


<!DOCTYPE html>
<html lang="en-CA">
  <head>
    <title>
    Management of Chronic Non-Cancer Pain |     Centre for Effective Practice - Digital Tools        </title>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width" />
  <meta name="theme-color" content="#999999" />
  <link href="https://fonts.googleapis.com/css?family=Montserrat:500,500i,700,700i|Open+Sans:400,400i,700,700i&display=swap" rel="stylesheet">
  <meta name='robots' content='noindex, nofollow' />
	<style>img:is([sizes="auto" i], [sizes^="auto," i]) { contain-intrinsic-size: 3000px 1500px }</style>
	<link rel='dns-prefetch' href='//a.omappapi.com' />
<link rel='dns-prefetch' href='//www.googletagmanager.com' />
		<!-- This site uses the Google Analytics by MonsterInsights plugin v9.5.3 - Using Analytics tracking - https://www.monsterinsights.com/ -->
							<script src="//www.googletagmanager.com/gtag/js?id=G-G1F4BDXK7E"  data-cfasync="false" data-wpfc-render="false" type="text/javascript" async></script>
			<script data-cfasync="false" data-wpfc-render="false" type="text/javascript">
				var mi_version = '9.5.3';
				var mi_track_user = true;
				var mi_no_track_reason = '';
								var MonsterInsightsDefaultLocations = {"page_location":"https:\/\/tools.cep.health\/tool\/management-of-chronic-non-cancer-pain\/"};
				if ( typeof MonsterInsightsPrivacyGuardFilter === 'function' ) {
					var MonsterInsightsLocations = (typeof MonsterInsightsExcludeQuery === 'object') ? MonsterInsightsPrivacyGuardFilter( MonsterInsightsExcludeQuery ) : MonsterInsightsPrivacyGuardFilter( MonsterInsightsDefaultLocations );
				} else {
					var MonsterInsightsLocations = (typeof MonsterInsightsExcludeQuery === 'object') ? MonsterInsightsExcludeQuery : MonsterInsightsDefaultLocations;
				}

								var disableStrs = [
										'ga-disable-G-G1F4BDXK7E',
									];

				/* Function to detect opted out users */
				function __gtagTrackerIsOptedOut() {
					for (var index = 0; index < disableStrs.length; index++) {
						if (document.cookie.indexOf(disableStrs[index] + '=true') > -1) {
							return true;
						}
					}

					return false;
				}

				/* Disable tracking if the opt-out cookie exists. */
				if (__gtagTrackerIsOptedOut()) {
					for (var index = 0; index < disableStrs.length; index++) {
						window[disableStrs[index]] = true;
					}
				}

				/* Opt-out function */
				function __gtagTrackerOptout() {
					for (var index = 0; index < disableStrs.length; index++) {
						document.cookie = disableStrs[index] + '=true; expires=Thu, 31 Dec 2099 23:59:59 UTC; path=/';
						window[disableStrs[index]] = true;
					}
				}

				if ('undefined' === typeof gaOptout) {
					function gaOptout() {
						__gtagTrackerOptout();
					}
				}
								window.dataLayer = window.dataLayer || [];

				window.MonsterInsightsDualTracker = {
					helpers: {},
					trackers: {},
				};
				if (mi_track_user) {
					function __gtagDataLayer() {
						dataLayer.push(arguments);
					}

					function __gtagTracker(type, name, parameters) {
						if (!parameters) {
							parameters = {};
						}

						if (parameters.send_to) {
							__gtagDataLayer.apply(null, arguments);
							return;
						}

						if (type === 'event') {
														parameters.send_to = monsterinsights_frontend.v4_id;
							var hookName = name;
							if (typeof parameters['event_category'] !== 'undefined') {
								hookName = parameters['event_category'] + ':' + name;
							}

							if (typeof MonsterInsightsDualTracker.trackers[hookName] !== 'undefined') {
								MonsterInsightsDualTracker.trackers[hookName](parameters);
							} else {
								__gtagDataLayer('event', name, parameters);
							}
							
						} else {
							__gtagDataLayer.apply(null, arguments);
						}
					}

					__gtagTracker('js', new Date());
					__gtagTracker('set', {
						'developer_id.dZGIzZG': true,
											});
					if ( MonsterInsightsLocations.page_location ) {
						__gtagTracker('set', MonsterInsightsLocations);
					}
										__gtagTracker('config', 'G-G1F4BDXK7E', {"forceSSL":"true","link_attribution":"true","page_path":location.pathname + location.search + location.hash} );
															window.gtag = __gtagTracker;										(function () {
						/* https://developers.google.com/analytics/devguides/collection/analyticsjs/ */
						/* ga and __gaTracker compatibility shim. */
						var noopfn = function () {
							return null;
						};
						var newtracker = function () {
							return new Tracker();
						};
						var Tracker = function () {
							return null;
						};
						var p = Tracker.prototype;
						p.get = noopfn;
						p.set = noopfn;
						p.send = function () {
							var args = Array.prototype.slice.call(arguments);
							args.unshift('send');
							__gaTracker.apply(null, args);
						};
						var __gaTracker = function () {
							var len = arguments.length;
							if (len === 0) {
								return;
							}
							var f = arguments[len - 1];
							if (typeof f !== 'object' || f === null || typeof f.hitCallback !== 'function') {
								if ('send' === arguments[0]) {
									var hitConverted, hitObject = false, action;
									if ('event' === arguments[1]) {
										if ('undefined' !== typeof arguments[3]) {
											hitObject = {
												'eventAction': arguments[3],
												'eventCategory': arguments[2],
												'eventLabel': arguments[4],
												'value': arguments[5] ? arguments[5] : 1,
											}
										}
									}
									if ('pageview' === arguments[1]) {
										if ('undefined' !== typeof arguments[2]) {
											hitObject = {
												'eventAction': 'page_view',
												'page_path': arguments[2],
											}
										}
									}
									if (typeof arguments[2] === 'object') {
										hitObject = arguments[2];
									}
									if (typeof arguments[5] === 'object') {
										Object.assign(hitObject, arguments[5]);
									}
									if ('undefined' !== typeof arguments[1].hitType) {
										hitObject = arguments[1];
										if ('pageview' === hitObject.hitType) {
											hitObject.eventAction = 'page_view';
										}
									}
									if (hitObject) {
										action = 'timing' === arguments[1].hitType ? 'timing_complete' : hitObject.eventAction;
										hitConverted = mapArgs(hitObject);
										__gtagTracker('event', action, hitConverted);
									}
								}
								return;
							}

							function mapArgs(args) {
								var arg, hit = {};
								var gaMap = {
									'eventCategory': 'event_category',
									'eventAction': 'event_action',
									'eventLabel': 'event_label',
									'eventValue': 'event_value',
									'nonInteraction': 'non_interaction',
									'timingCategory': 'event_category',
									'timingVar': 'name',
									'timingValue': 'value',
									'timingLabel': 'event_label',
									'page': 'page_path',
									'location': 'page_location',
									'title': 'page_title',
									'referrer' : 'page_referrer',
								};
								for (arg in args) {
																		if (!(!args.hasOwnProperty(arg) || !gaMap.hasOwnProperty(arg))) {
										hit[gaMap[arg]] = args[arg];
									} else {
										hit[arg] = args[arg];
									}
								}
								return hit;
							}

							try {
								f.hitCallback();
							} catch (ex) {
							}
						};
						__gaTracker.create = newtracker;
						__gaTracker.getByName = newtracker;
						__gaTracker.getAll = function () {
							return [];
						};
						__gaTracker.remove = noopfn;
						__gaTracker.loaded = true;
						window['__gaTracker'] = __gaTracker;
					})();
									} else {
										console.log("");
					(function () {
						function __gtagTracker() {
							return null;
						}

						window['__gtagTracker'] = __gtagTracker;
						window['gtag'] = __gtagTracker;
					})();
									}
			</script>
				<!-- / Google Analytics by MonsterInsights -->
		<link rel='stylesheet' id='wp-block-library-css' href='https://tools.cep.health/wp-includes/css/dist/block-library/style.min.css?ver=6.8.2' media='all' />
<style id='classic-theme-styles-inline-css' type='text/css'>
/*! This file is auto-generated */
.wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none}
</style>
<style id='global-styles-inline-css' type='text/css'>
:root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}
:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}
:root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;}
</style>
<link rel='stylesheet' id='studio123_styles-css' href='https://tools.cep.health/wp-content/themes/cep-tools/style.min.css?ver=1743561782' media='all' />
<link rel='stylesheet' id='glossary-hint-css' href='https://tools.cep.health/wp-content/plugins/glossary-by-codeat/assets/css/tooltip-classic.css?ver=2.3.5' media='all' />
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/google-analytics-for-wordpress/assets/js/frontend-gtag.min.js?ver=9.5.3" id="monsterinsights-frontend-script-js" async="async" data-wp-strategy="async"></script>
<script data-cfasync="false" data-wpfc-render="false" type="text/javascript" id='monsterinsights-frontend-script-js-extra'>/* <![CDATA[ */
var monsterinsights_frontend = {"js_events_tracking":"true","download_extensions":"doc,pdf,ppt,zip,xls,docx,pptx,xlsx","inbound_paths":"[{\"path\":\"\\\/go\\\/\",\"label\":\"affiliate\"},{\"path\":\"\\\/recommend\\\/\",\"label\":\"affiliate\"}]","home_url":"https:\/\/tools.cep.health","hash_tracking":"true","v4_id":"G-G1F4BDXK7E"};/* ]]> */
</script>

<!-- Google tag (gtag.js) snippet added by Site Kit -->

<!-- Google Analytics snippet added by Site Kit -->
<script type="text/javascript" src="https://www.googletagmanager.com/gtag/js?id=GT-MBGGM43" id="google_gtagjs-js" async></script>
<script type="text/javascript" id="google_gtagjs-js-after">
/* <![CDATA[ */
window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);}
gtag("set","linker",{"domains":["tools.cep.health"]});
gtag("js", new Date());
gtag("set", "developer_id.dZTNiMT", true);
gtag("config", "GT-MBGGM43");
/* ]]> */
</script>

<!-- End Google tag (gtag.js) snippet added by Site Kit -->
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/jquery.min.js" id="jquery-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/jquery-migrate.min.js" id="jquery-migrate-js"></script>
<link rel="https://api.w.org/" href="https://tools.cep.health/wp-json/" /><link rel="alternate" title="JSON" type="application/json" href="https://tools.cep.health/wp-json/wp/v2/tools/68657" /><link rel="alternate" title="oEmbed (JSON)" type="application/json+oembed" href="https://tools.cep.health/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ftools.cep.health%2Ftool%2Fmanagement-of-chronic-non-cancer-pain%2F" />
<link rel="alternate" title="oEmbed (XML)" type="text/xml+oembed" href="https://tools.cep.health/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ftools.cep.health%2Ftool%2Fmanagement-of-chronic-non-cancer-pain%2F&#038;format=xml" />
<meta name="generator" content="Site Kit by Google 1.155.0" />
<!-- Google Tag Manager snippet added by Site Kit -->
<script type="text/javascript">
/* <![CDATA[ */

			( function( w, d, s, l, i ) {
				w[l] = w[l] || [];
				w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} );
				var f = d.getElementsByTagName( s )[0],
					j = d.createElement( s ), dl = l != 'dataLayer' ? '&l=' + l : '';
				j.async = true;
				j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
				f.parentNode.insertBefore( j, f );
			} )( window, document, 'script', 'dataLayer', 'GTM-WLFDZV' );
			
/* ]]> */
</script>

<!-- End Google Tag Manager snippet added by Site Kit -->
<link rel="icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-32x32.png" sizes="32x32" />
<link rel="icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-192x192.png" sizes="192x192" />
<link rel="apple-touch-icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-180x180.png" />
<meta name="msapplication-TileImage" content="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-270x270.png" />
		<style type="text/css" id="wp-custom-css">
			.m0 {margin-top:0; margin-bottom: 0}		</style>
		<!--- Error: No Google analytics ID found. Go to Site Options > Analytics to enter your ID. ---><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({"gtm.start":new Date().getTime(),event:"gtm.js"});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!="dataLayer"?"&l="+l:"";j.async=true;j.src="https://www.googletagmanager.com/gtm.js?id="+i+dl;f.parentNode.insertBefore(j,f);})(window,document,"script","dataLayer","GTM-K6HPX8H");</script>  </head>
  <body class="wp-singular tools-template-default single single-tools postid-68657 wp-theme-cep-tools management-of-chronic-non-cancer-pain">

      <!-- Google Tag Manager (noscript) -->
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K6HPX8H"
    height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <header>
      <div class="container">
        <div class="columns is-flex is-gapless">
          <div class="column">
            <a class="logo" target="_self" href="https://cep.health/tools" data-wpel-link="external" rel="external noopener noreferrer">
              <img src="https://tools.cep.health/wp-content/themes/cep-tools/img/logo.svg" alt="Centre for Effective Practice - Digital Tools" />
            </a>
          </div>
        </div>
      </div>
    </header>

<main>
  	<section class="section--impact_area">
    <div class="container">
        <h1>Management of Chronic Non-Cancer Pain</h1>
                <ul class="links">
            <li>
                <button data-search-content class="button">Search Content&nbsp;&nbsp;<i class="icon icon-search"></i></a>
            </li>
                    </ul>
    </div>
</section>

		<section class="section--sections_listing" id="sections">

			
<div class="search-tool">
    <div class="search-tool-bar">
        <div class="search-wrapper">
            <div class="search-input-wrapper">
                <input data-search-tool-input type="search" autocomplete="off" placeholder="Enter search terms">
                <i class="icon icon-search"></i>
                <span class="search-no-results-found">No Results Found</span>
                <span class="search-result-count"><span class="current">0</span>/<span class="total">0</span></span>
            </div>
            <button data-search-previous disabled class="search-previous"><i class="icon icon-chevron-up"></i></button>
            <button data-search-next disabled class="search-next"><i class="icon icon-chevron-down"></i></button>
        </div>
        <button data-search-tool-close class="close"><i class="icon icon-close"></i></button>
    </div>
</div>
			<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>This tool is designed to help family physicians and nurse practitioners (primary care providers) develop and implement a management plan for adult patients with chronic non-cancer pain (CNCP) in the primary care setting. CNCP is defined as pain that typically persists or recurs for more than 3 months or past the time of normal tissue healing.<sup>1-4</sup> This tool applies to, but is not limited to pain conditions such as osteoarthritis, low back pain, musculoskeletal pain, fibromyalgia and neuropathic pain. </p>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Eye.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>See <a href="https://tools.cep.health/wp-admin/post.php?post=41&amp;action=edit#supporting-materials-and-resources" data-wpel-link="internal">Supporting material and resources</a> and <a href="https://tools.cep.health/wp-admin/post.php?post=41&amp;action=edit#references/" data-wpel-link="internal">References</a> for links to tools and guidelines to assist with diagnosis.</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Yellow-Notice.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p><em data-rich-text-format-boundary="true">Please note, this tool is not suitable for use in the management of acute pain and is not designed to assist in diagnosing various CNCP conditions. Management of chronic pelvic pain is not within the scope of this tool.</em></p>
          </div>
        </div>

      </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h4 class="wp-block-heading">Introduction</h4>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>This tool focuses on a multi-modal approach to manage CNCP. Primary care providers should use non-pharmacological options, with or without pharmacological options, to build a comprehensive and personalized plan that incorporates the patient’s goals.<sup>3</sup></p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">General approach</h5>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>Work with your patients to identify and understand the complex bio-psycho-social elements involved in their pain and emphasize the value of a multi-modal approach to manage their pain. <strong>Management is often a process of repeated trials to determine the effects of specific treatments and can take a few months or years to optimize.</strong> Once a treatment plan is identified, initiate, adapt and evaluate how it improves daily function, pain, mood and quality of life, while assessing the risks/benefits for long-term use. It is also important to optimally manage any active underlying health issues related to a patient’s pain (e.g. diabetes, inflammatory arthritis). </p>
</div></article>

<article class="block--table ">
<div class="container">
  <div class="table no-header inner-border-blue blue">

        
                    <div class="rows">

                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:30%;">
                                            <h6><strong>Step 1: Assess</strong></h6>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:80%;">
                                            <p>Begin to develop a rapport with the patient to encourage trust and information sharing. <strong>Start with a thorough baseline assessment</strong>, which you may need to be completed over more than one visit.<sup>1</sup></p>
<p><strong>Jump to:<br />
<a href="#baseline-and-ongoing-assessment">Baseline and ongoing assessment</a></strong></p>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:30%;">
                                            <h6><strong>Step 2: Create a management plan</strong></h6>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:80%;">
                                            <p>Based on the assessment, identify the <strong>non-pharmacological and/or pharmacological treatments</strong> that you and your patient feel comfortable starting.</p>
<p><strong>Jump to:<br />
</strong><a href="#management-plan">Management plan</a><br />
<a href="#non-pharmacological-therapies">Non-pharmacological therapies</a><br />
<a href="#non-opioid-medications">Non-opioid medications</a><br />
<a href="#opioid-medications">Opioid medications</a></p>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:30%;">
                                            <h6><strong>Step 3: Initiate, adapt and evaluate treatment(s)</strong></h6>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:80%;">
                                            <p><strong data-rich-text-format-boundary="true">Use the patient record and treatment plan</strong> to help initiate, adapt and evaluate the non-pharmacological and/or pharmacological treatments on an ongoing basis.</p>
<p><strong>Jump to:<br />
</strong><a href="#management-plan">Management plan</a><br />
<a href="#non-pharmacological-therapies">Non-pharmacological therapies</a><br />
<a href="#non-opioid-medications">Non-opioid medications</a><br />
<a href="#opioid-medications">Opioid medications</a></p>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:30%;">
                                            <h6><strong>Step 4: Refer, as appropriate</strong></h6>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:80%;">
                                            <p>When appropriate, consider <strong>referral</strong> to a specialist or multidisciplinary clinic.</p>
<p><strong>Jump to:<br />
</strong><a href="#intervention-management-and-referral">Intervention management and referral</a><strong><br />
</strong></p>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                
            </div>
        
        
    </div>
</div>
</article>			<div class="container has-text-right" style="padding: 0 0 1.5rem;">
				<div class="expand-all">
					<a href="#" data-expand-text="Expand All" data-collapse-text="Collapse All">Expand All</a>
				</div>
			</div>
			<div id="top-of-sections"></div>
							<section class="main-section" id="baseline-and-ongoing-assessment" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Baseline and ongoing assessment								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>The Baseline and Ongoing Assessment guides are designed to help develop and monitor a treatment plan for patients with CNCP. <strong>They are not designed to diagnose specific CNCP conditions.</strong> Consider completing a thorough Baseline Assessment for the following:</p>
<ul>
<li>Patients with a new diagnosis of CNCP</li>
<li>Patients who are new to your practice with a diagnosis of CNCP</li>
<li>Patients currently in your practice with a diagnosis of CNCP</li>
</ul>
          </div>
        </div>

      </div>
</article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--faq "><div class="container">
    <div class="faq-title-wrapper">
        <div class="faq-icon-wrapper">
            <img decoding="async" class="faq-icon" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" alt="" />
        </div>
        <h3 class="faq-title">Guidance on conducting a baseline assessment</h3>
    </div>
            <div class="questions">
                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Pain condition and physical examination</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Identify pain diagnoses (e.g. osteoarthritis, fibromyalgia, neuropathic pain, etc.)</li>
<li>Document relevant physical examination based on diagnosed pain condition(s)</li>
<li>If suspected <a href="https://link.cep.health/cncpweb2" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Complex Regional Pain Syndrome (CRPS)</a>, consider urgent referral</li>
<li>Complete <a href="https://link.cep.health/cncpweb3" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Brief Pain Inventory (BPI)</a>: intensity; exacerbating and alleviating factors; character; systemic symptoms; duration, assess functional status and impairment</li>
<li>Past investigations/consultations</li>
<li>Response to current/past treatments (consider whether trial was long enough to evaluate efficacy/side effects)</li>
<li>Past medical history</li>
<li>Current medications (including prescription, non-prescription, and natural products)</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Functional and social history</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Assess functional status and impairment (e.g. <a href="https://link.cep.health/cncpweb3" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">BPI</a>)</li>
<li>Psychosocial history: living arrangements; family/social support; family obligations; work status; sleep; relationships</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Mental health</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Current and past psychiatric history (e.g. depression <a href="https://link.cep.health/cncpweb4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">PHQ-9</a>, anxiety <a href="https://link.cep.health/cncpweb5" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">GAD-7</a>, PTSD)</li>
<li>Family psychiatric history</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Substance use history and opioid risk assessment</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Review history of substance use, abuse, and addiction (start with family history then personal)</li>
<li>Alcohol, cannabis, prescription medications, illicit drugs Attendance at an addiction treatment program</li>
<li>If on opioids, review for the presence of any opioid use disorder features. May use <a href="https://link.cep.health/cncpweb6" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid Risk Tool</a>, however, it has insufficient accuracy for risk stratification</li>
<li>Use urine drug testing before starting opioid therapy. Consider annual urine drug testing (or more often, as appropriate) for the use of opioid medication and/or illicit drugs</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Yellow Flags*</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Assess the following to identify patients with CNCP who are at risk for poor outcomes:
<ul>
<li><strong>Biomedical</strong>: severe pain or increased disability at presentation; previous significant pain episodes; multi-site pain; non-organic signs; iatrogenic factors</li>
<li><strong>Psychological</strong>: belief that pain indicates harm; expectation that passive rather than active treatments are most helpful; fear-avoidance behaviour; catastrophic thinking; poor problem-solving ability; passive coping strategies; atypical health beliefs; psychosomatic perceptions; high levels of distress</li>
<li><strong>Social</strong>: low expectations of return to work; lack of confidence in performing work activities; heavier workload; low levels of control over rate of workload; poor work relationships; social dysfunction/isolation; medico-legal issues</li>
</ul>
</li>
</ul>
                        </div>
                    </div>
                                    </div>
    </div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--faq "><div class="container">
    <div class="faq-title-wrapper">
        <div class="faq-icon-wrapper">
            <img decoding="async" class="faq-icon" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" alt="" />
        </div>
        <h3 class="faq-title">Guidance on conducting an ongoing assessment</h3>
    </div>
            <div class="questions">
                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Pain condition and physical examination</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Identify new pain, related symptoms or significant change (physical examination as indicated)</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Monitor Yellow Flags*</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Assess the following to identify patients with CNCP who are at risk for poor outcomes:
<ul>
<li><strong>Biomedical</strong>: severe pain or increased disability at presentation; previous significant pain episodes; multi-site pain; non-organic signs; iatrogenic factors</li>
<li><strong>Psychological</strong>: belief that pain indicates harm; expectation that passive rather than active treatments are most helpful; fear-avoidance behaviour; catastrophic thinking; poor problem-solving ability; passive coping strategies; atypical health beliefs; psychosomatic perceptions; high levels of distress</li>
<li><strong>Social</strong>: Low expectations of return to work; lack of confidence in performing work activities; heavier workload; low levels of control over rate of workload; poor work relationships; social dysfunction/isolation; medico-legal issues</li>
</ul>
</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Response to treatment</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <p><em>Note: 30% improvement is meaningful for pain and function<sup>2</sup></em></p>
<ul>
<li>Assess using validated tools (e.g.<a href="https://link.cep.health/cncpweb3" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">BPI</a>)</li>
<li>Monitor adherence to pharmacological and pharmacological therapies</li>
<li>Monitor adverse events</li>
<li>Determine effect on pain, function, quality of life, mood and social function</li>
<li>Progress towards patient&#8217;s SMART (Specific, Measurable, Agreed-upon, Realistic, Time-based) goals, e.g. taking walks, attending family/social events, returning to part-time work, participating in recreational activities</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Substance use and opioid risk assessment</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>If on opioids, monitor for aberrant drug-related behaviours, <a href="#opioid-medications">clinical features of Opioid Use Disorder</a></li>
<li>Use urine drug testing as indicated</li>
<li>In patients with current or past substance use disorder (SUD), monitor for destabilization of disease</li>
<li>Monitor for aberrant use of prescribed medications</li>
</ul>
                        </div>
                    </div>
                                    </div>
    </div></article></div>
</div>


<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="has-small-font-size"><em>* Patients at higher risk of poor outcomes may require closer follow-up and greater emphasis on a diversified non-pharmacological and pharmacological, multi-modal approach to treatment<sup>6</sup></em></p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="management-plan" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Management plan								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>Based on the assessment, identify the non-pharmacological and/or pharmacological treatments that you and your patient feel comfortable starting. <strong>To learn more about the non-pharmacological and/or pharmacological options, considerations and guidance on initiating, adapting, and evaluating treatments click on the relevant sections below.</strong></p>
</div></article>

<article class="block--file-download ">
<div class="container">
  <a href="https://tools.cep.health/wp-content/uploads/2019/10/cncp-patient-record-treatment-plan.pdf" download="" target="_blank" class="inner" data-wpel-link="internal">
    <div class="inner-wrapper">
      <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/file.svg" />
      <div class="filename-wrapper">
        <h6>Patient record and treatment plan</h6>
        <span class="filename">cncp-patient-record-treatment-plan.pdf</span>
      </div>
    </div>
    <span class="button" target="_blank"><i class="icon-arrow-down-circ"></i> Download</span>
  </a>
</div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>This patient record and treatment plan is designed to help providers document the ‘agreed-on’ plan that can be filed in a patient’s chart and referred to during subsequent visits to follow up and continue discussion. Download the patient record and treatment plan to help initiate, adapt and evaluate the agreed upon non-pharmacological and/or pharmacological treatments.  </p>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p></p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="non-pharmacological-therapies" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Non-pharmacological therapies								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <div class="columns is-flex is-gapless">
<div class="column is-10-mobile is-11">
<p>Non-pharmacological treatments should be considered for all patients with CNCP.<sup>1</sup> Choose treatments that you and the patient feel comfortable with and then initiate, adapt, and evaluate the treatment plan (use motivational interviewing techniques, as appropriate).</p>
</div>
</div>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Eye.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p><strong>When determining the benefit of a therapy, an improvement of 30% in pain and function scores is considered clinically meaningful;<sup>2</sup> however, even a smaller improvement may be meaningful to the patient.</strong></p>
          </div>
        </div>

      </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Recommendations</h5>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <ul>
<li>Exercise, regardless of form, is recommended for the management of chronic non-cancer pain<sup>1</sup></li>
<li>Cognitive behavioural therapy (CBT) should be considered for the treatment of patients with chronic pain<sup><a href="https://www.tools.cep.health/tool/management-of-chronic-non-cancer-pain/?preview_id=41&amp;preview_nonce=9d576fdadb&amp;preview=true#references" data-wpel-link="internal">1</a></sup></li>
</ul>
          </div>
        </div>

      </div>
</article>

<article class="block--faq "><div class="container">
    <div class="faq-title-wrapper">
        <div class="faq-icon-wrapper">
            <img decoding="async" class="faq-icon" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" alt="" />
        </div>
        <h3 class="faq-title">Tips on initating treatment(s)</h3>
    </div>
            <div class="questions">
                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Physical activity/exercises</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Recommend general activity and exercise therapies, as appropriate</li>
<li>Recommend combined home and group physical activities to help increase overall activity levels</li>
<li>If the patient is reluctant to try physical activity/exercise therapies try the Elicit-Provide-Elicit technique:<sup>7,8</sup>
<ul>
<li>Elicit the patient’s thoughts/feelings: “How do you feel about trying some exercise therapy for your pain?”</li>
<li>Provide information: A common patient concern is that exercise therapy will increase pain: “If I understand correctly, you are concerned that physical activity will increase your pain. Interestingly, it actually tends to do the opposite; physical activity can be an effective way of decreasing pain.”</li>
<li>Elicit the patient’s opinion: “What do you think about this?”</li>
</ul>
</li>
<li>Pick a low impact physical activity, such as walking, pilates, Tai Chi, yoga or aquatic therapy</li>
<li>Start low and go slow (e.g. 5 min every other day) and aim for a moderate level of intensity of activity<sup><a href="https://www.tools.cep.health/tool/management-of-chronic-non-cancer-pain/?preview_id=41&amp;preview_nonce=9d576fdadb&amp;preview=true#references" data-wpel-link="internal">2,9</a></sup></li>
<li>Consider referral to a physiotherapist if more intensive support is required</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Psychological therapies</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Particularly valuable for those with co-morbid depression and/ or anxiety</li>
<li>Start with one of the following psychological therapies: CBT, Mindfulness Based Intervention (MBI), Acceptance Commitment Therapy or Respondent Behavioural Therapy</li>
<li>Consider referral to a psychotherapist, social worker, occupational therapist and/or other mental health professional if more intensive support is required</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Self-management programs</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>A self-management program should be considered to complement other therapies patients have initiated<sup><a href="https://www.tools.cep.health/tool/management-of-chronic-non-cancer-pain/?preview_id=41&amp;preview_nonce=9d576fdadb&amp;preview=true#references" data-wpel-link="internal">1</a></sup></li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Physical therapies</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Consider any of the following for short-term relief of pain:<sup>1</sup>
<ul>
<li>Manual therapy</li>
<li>TENS</li>
<li>Low level laser therapy</li>
</ul>
</li>
<li>Consider referral to a physiotherapist, chiropractor or osteopath, as appropriate</li>
</ul>
                        </div>
                    </div>
                                    </div>
    </div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--faq "><div class="container">
    <div class="faq-title-wrapper">
        <div class="faq-icon-wrapper">
            <img decoding="async" class="faq-icon" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" alt="" />
        </div>
        <h3 class="faq-title">Tips on adapting treatment(s)</h3>
    </div>
            <div class="questions">
                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Physical activity/exercises</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Improve adherence to home physical activity by encouraging graded activity: add 10 min every 3-4 weeks<sup><a href="https://www.tools.cep.health/tool/management-of-chronic-non-cancer-pain/?preview_id=41&amp;preview_nonce=9d576fdadb&amp;preview=true#references" data-wpel-link="internal">10</a></sup></li>
<li>Minimal goal: 30 min of exercise 5 days a week<sup><a href="https://www.tools.cep.health/tool/management-of-chronic-non-cancer-pain/?preview_id=41&amp;preview_nonce=9d576fdadb&amp;preview=true#references" data-wpel-link="internal">2,11</a></sup></li>
<li>Add in other activities as tolerated</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Psychological therapies</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Encourage patients to continue to use strategies learned from therapies</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Self-management programs</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Encourage patients to continue to use strategies learned from the program</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Physical therapies</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Encourage patients to participate in 8 therapy sessions over 4-6 weeks<sup>12</sup></li>
</ul>
                        </div>
                    </div>
                                    </div>
    </div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--faq "><div class="container">
    <div class="faq-title-wrapper">
        <div class="faq-icon-wrapper">
            <img decoding="async" class="faq-icon" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" alt="" />
        </div>
        <h3 class="faq-title">Tips on evaluating treatment(s)</h3>
    </div>
            <div class="questions">
                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Physical activity/exercises</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Measure benefits at 8 or more weeks<sup><a href="https://www.tools.cep.health/tool/management-of-chronic-non-cancer-pain/?preview_id=41&amp;preview_nonce=9d576fdadb&amp;preview=true#references" data-wpel-link="internal">11</a></sup></li>
<li>Use <a href="https://link.cep.health/cncpweb3" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">BPI</a> to evaluate effect on pain, function and quality of life</li>
<li>If benefits are not identified, try other activity types and continue to counsel about the value of exercise and activity</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Psychological therapies</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Use tools like <a href="https://link.cep.health/cncpweb3" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">BPI</a>, <a href="https://link.cep.health/cncpweb4" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">PHQ-9</a> to evaluate effect on pain, function and quality of life</li>
<li>Add other types of therapies as appropriate</li>
<li>Rarely, may exacerbate some underlying mental illnesses</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Self-management programs</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>After program completion use tools like <a href="https://link.cep.health/cncpweb3" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">BPI</a> to evaluate effect on pain, function and quality of life</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Physical therapies</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <ul>
<li>Follow up after completion of 8 sessions</li>
<li>Use <a href="https://link.cep.health/cncpweb3" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">BPI</a> to evaluate effect on pain, function and quality of life</li>
</ul>
                        </div>
                    </div>
                                    </div>
    </div></article></div>
</div>


<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Options</h5>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h4 class="wp-block-heading">Physical activity/exercises<sup>1,20,21</sup></h4>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Aerobic exercise (e.g. walking)</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence<br />
••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Improved global well being and physical function, reduced pain<sup>20</sup></span></li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Strengthening exercise (e.g. lifting weights)</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
<li><span style="font-size: 14px;"><span style="font-size: 14px;">Non-specific low back pain</span></span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Global well being, pain and physical function (fibromyalgia<sup>20</sup>)</span></li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Core stabilising exercises (e.g. pilates)</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
<li><span style="font-size: 14px;">Non-specific low back pain</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Not reported in guideline</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Reducing pain (non-specific low back pain<sup>1</sup>, fibromyalgia<sup>20</sup>)</span></li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Tai Chi</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
<li><span style="font-size: 14px;">Chronic arthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Not reported in guideline</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Reducing pain, improving disability (arthritis<sup>1</sup>), quality of life (fibromyalgia<sup>20</sup>)</span></li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Yoga (any type)</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
<li><span style="font-size: 14px;">Headache</span></li>
<li><span style="font-size: 14px;"> Low back pain</span></li>
<li><span style="font-size: 14px;">Rheumatoid arthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Not reported in guideline</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Reducing pain and disability (headache, back pain, rheumatoid arthritis<sup>21</sup>)</span></li>
<li><span style="font-size: 14px;">Improved quality of life, pain and function (fibromyalgia<sup>20</sup>)</span></li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Therapeutic aquatic exercise</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
<li><span style="font-size: 14px;">Headache</span></li>
<li><span style="font-size: 14px;">Low back pain</span></li>
<li><span style="font-size: 14px;">Rheumatoid arthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Improved pain, quality of life, physical function, muscle strength (fibromyalgia<sup>20</sup>, low back pain<sup>1</sup>)</span></li>
</ul>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Psychological therapies</h6>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Cognitive Behavioural Therapy (CBT)</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Orofacial pain</span></li>
<li><span style="font-size: 14px;">Low back pain</span></li>
<li><span style="font-size: 14px;"> Neck pain</span></li>
<li><span style="font-size: 14px;">Rheumatoid arthritis</span></li>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>L</strong></span><span style="font-size: 14px;"><strong>evel of evidence<br />
••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Reduced pain (orofacial, low back pain, fibromyalgia)<sup>1,23</sup>; </span><span style="font-size: 14px;">reduced use of analgesics (low back pain); r</span><span style="font-size: 14px;">educed disability (low back pain<sup>1</sup>, fibromyalgia<sup>23</sup>); </span><span style="font-size: 14px;">improved quality of life (low back pain); </span><span style="font-size: 14px;">improved coping (low back pain, fibromyalgia); </span><span style="font-size: 14px;">reduced depression (low back pain<sup>1</sup>, fibromyalgia<sup>3</sup>); </span><span style="font-size: 14px;">reduced physician visits (low back pain); </span><span style="font-size: 14px;">mproved sleep<sup>1</sup></span></li>
</ul>
<p><strong><span style="font-size: 14px;">Harms</span></strong></p>
<ul>
<li><span style="font-size: 14px;">Rarely may include worsening of co-existing mental disorders</span></li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Mindfulness based interventions</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
<li><span style="font-size: 14px;">Low back pain</span></li>
<li><span style="font-size: 14px;">Rheumatoid arthritis</span></li>
<li><span style="font-size: 14px;">Musculoskeletal pain</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence<br />
••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Reduced pain, reduced depression and anxiety, improved quality of life</span></li>
</ul>
<p><strong><span style="font-size: 14px;">Harms</span></strong></p>
<ul>
<li><span style="font-size: 14px;">Not reported in guideline</span></li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Acceptance and Commitment Therapy</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
<li><span style="font-size: 14px;">Neuropathic pain</span></li>
<li><span style="font-size: 14px;"> Low back pain</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;"> Improved depression and anxiety</span></li>
</ul>
<p><strong><span style="font-size: 14px;">Harms</span></strong></p>
<ul>
<li><span style="font-size: 14px;">Not reported in guideline</span></li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Respondent behavioural therapies</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Low back pain</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Short term pain reduction, reduction in disability</span></li>
<li><span style="font-size: 14px;">No better than Cognitive Behavioural Therapy</span></li>
</ul>
<p><strong><span style="font-size: 14px;">Harms</span></strong></p>
<ul>
<li><span style="font-size: 14px;">Not reported in guideline</span></li>
</ul>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Self-management programs<sup>12</sup> and <strong>physical therapies</strong></h6>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Self-management programs</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
<li><span style="font-size: 14px;">Rheumatoid arthritis</span></li>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
<li><span style="font-size: 14px;">Low back pain</span></li>
<li><span style="font-size: 14px;">Neck pain</span></li>
<li><span style="font-size: 14px;">Shoulder pain</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence<br />
</strong><span style="font-size: 14px;">••</span></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Reduced pain and disability (arthritis)<sup>20</sup></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="fZbYV0">View Additional Content</a>
                                      </div>
                                      <div class="modal" data-modal="fZbYV0">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Self-management program characteristics</strong></p>
<ul>
<li>Primarily educational using interactive and collaborative method often run by patients</li>
<li>Focus on taking an active part in managing their pain</li>
<li>Delivered as: individuals, face-to-face or electronically</li>
<li>Content may include: education around goal setting, self-monitoring, psychological and rehabilitation interventions (e.g. exercise therapies)</li>
</ul>
<p><strong>Harms</strong></p>
<ul>
<li>Possible increased pain with exercise, resulting in drop out from programs: if this occurs, explore with the patient how best to help them cope<sup>21</sup></li>
<li style="list-style-type: none;"></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Manual therapy</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Low back pain</span></li>
<li><span style="font-size: 14px;">Neck pain</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Manual therapy should be considered for short term pain relief of patients with chronic low back pain</span></li>
<li><span style="font-size: 14px;">Manual therapy in combination with exercise should be considered for the treatment of patients with chronic neck pain</span></li>
<li><span style="font-size: 14px;">Short term: pain relief, functional improvement and cervicogenic headache<sup>1</sup></span></li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>TENS</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Neuropathic pain</span></li>
<li><span style="font-size: 14px;">Low back pain</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">TENS should be considered for the relief of chronic pain; either low or high frequency can be used</span></li>
<li><span style="font-size: 14px;">Pain (neuropathic pain)<sup>1</sup>, improved function (low back pain)<sup>1</sup></span></li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Low level laser therapy</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Low back pain</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Low level laser therapy should be considered as a treatment option for patients with chronic low back pain</span></li>
<li><span style="font-size: 14px;">Reduced pain<sup>1</sup></span></li>
</ul>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px"><em>LEGEND: CATEGORIES FOR LEVELS OF EVIDENCE (according to original guidelines’ taxonomy)<br><strong>•••</strong>   Highest level of evidence (meta-analyses; systematic reviews of RCTs; RCTs with varying levels of bias)&nbsp;<br><strong>••    </strong>Mid-level evidence (systematic reviews of case studies; high quality case control or cohort studies; experimental studies w/o randomization; case reports or studies)<br><strong>•</strong>     Low-level evidence (expert opinion and/or clinical experiences of respected authorities/guideline development group)&nbsp; </em></p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Resources</h5>
</div></article>

<article class="block--support-materials ">
  <div class="container two-column">
    <div class="columns is-variable is-8">

      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">For providers</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://link.cep.health/cncpweb1" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Resources in your LHIN</a></li>
<li><a href="https://link.cep.health/cncpweb39" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Appendix A: for details on evidence, benefits/harms, and dosing</a></li>
</ul>
        </div>
      </div>
  
      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">For patients</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://www.tools.cep.health/wp-content/uploads/2020/03/CNCP-PT-resource-for-web-2020.03.30.pdf" data-wpel-link="internal">Printable patient handout with resources on information on pain, non-pharmacological therapies, opioids, support groups and self-management programs</a></li>
<li><a href="https://link.cep.health/cncpweb24" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">RNAO Fact sheets: Helping people manage their pain</a></li>
<li><a href="https://link.cep.health/cncpweb24" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Understanding Pain in less than 5 minutes, and what to do about it!</a></li>
<li><a href="https://link.cep.health/cncpweb28" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">People in Pain Network</a></li>
<li><a href="https://link.cep.health/cncpweb29" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">British Columbia Chronic Pain Self-Management Program</a></li>
<li><a href="https://link.cep.health/cncpweb30" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">NeuroNovo Centre for Mindful Solutions (formerly “for Mindfulness-Based Chronic Pain Management”)</a></li>
<li><a href="https://link.cep.health/cncpweb31" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Fact Sheet: Chronic Pain</a></li>
<li><a href="https://link.cep.health/cncpweb32" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Webinar: Intro to Mindfulness for Chronic Pain  (5 part series)</a></li>
<li><a href="https://link.cep.health/cncpweb33" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Webinar: Yoga for people in pain (5 part series)</a></li>
<li><a href="https://link.cep.health/cncpweb34" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Canadian Mental Health Association (CMHA)</a></li>
</ul>
        </div>
      </div>

    </div>
  </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p></p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="non-opioid-medications" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Non-opioid medications								
    <span class="badge new" data-last-modified="Mar 19, 2021" data-hide-on-click>New</span>
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Non-opioid medications, in combination with non-pharmacological therapies, are the preferred treatment for CNCP.<sup>1 </sup>Choose a treatment that you and the patient feel comfortable with and then initiate, adapt, and evaluate the treatment plan.</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Eye.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p><strong>Most patients have either a good response (an improvement of 30% in pain and function scores is considered clinically meaningful) or have no response.<sup>2</sup></strong></p>
          </div>
        </div>

      </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Recommendations</h5>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Start with ONE medication and evaluate</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p><span data-rich-text-format-boundary="true">Use a sequential manner (versus parallel) to trial a second medication, if needed</span></p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p><span data-rich-text-format-boundary="true">Minimize polypharmacy as much as possible</span></p>
          </div>
        </div>

      </div>
</article>

<article class="block--multiple-choices ">
<div class="container">
    <div class="columns">
        <div class="column text">
            <div class="inner">
                                    <h6><img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/multiple-choices.svg" alt="Stack of papers." /> Click for tips on</h6>
                                            </div>
        </div>
    </div>
            <div class="columns">
            <div class="column choice-buttons">
                
                        
                        <button data-choice-button="1" class="green">Initiating treatment<sup>1</sup></button>
                        
                
                        
                        <button data-choice-button="2" class="green">Titrating treatment<sup>1</sup></button>
                        
                
                        
                        <button data-choice-button="3" class="green">Evaluating treatment<sup>13</sup></button>
                        
                            </div>
        </div>

        <div class="columns">
            <div class="column choice-content-wrapper">
                
                        
                        <div data-choice-content="1" class="choice-content">
                            <div class="table ">
                                                                    <div class="header">
                                                                                    <div class="heading">Initiating treatment<sup>1</sup></div>
                                                                            </div>
                                                                <div class="body">
                                                                    <div class="row">
                                                                            <div class="body no-heading">
                                            <p><strong><em>Some antidepressants can have a role for neuropathic pain, as well as for nociceptive pain, such as osteoarthritis</em></strong></p>
<ul>
<li>Select one medication based on patient’s pain type and professional judgment of risks/benefits</li>
<li>Agree with patient on goals (pain reduction, improved function/mood, other)</li>
<li>Agree on length of initial trial (usually 2 weeks at optimum dose, up to 4 weeks for antidepressants)</li>
<li>Discuss potential side effects/risks</li>
<li>Be aware of concomitant over-the-counter treatments and advise accordingly</li>
<li>Where possible, avoid concomitant sedative and hypnotic medications; be aware of concomitant alcohol use and counsel that there is an increased risk of overdose if alcohol and opioids are used together<sup>1,2</sup></li>
<li>Start at recommended dose</li>
</ul>

                                                                                </div>
                                                                    </div>
                                                            </div>
                        </div>
                    </div>
            
                
                        
                        <div data-choice-content="2" class="choice-content">
                            <div class="table ">
                                                                    <div class="header">
                                                                                    <div class="heading">Titrating treatment<sup>1</sup></div>
                                                                            </div>
                                                                <div class="body">
                                                                    <div class="row">
                                                                            <div class="body no-heading">
                                            <ul>
<li>Adjust, as needed, up to an effective dose, unless limited by side effects</li>
<li>Do not exceed the maximum dose</li>
</ul>

                                                                                </div>
                                                                    </div>
                                                            </div>
                        </div>
                    </div>
            
                
                        
                        <div data-choice-content="3" class="choice-content">
                            <div class="table ">
                                                                    <div class="header">
                                                                                    <div class="heading">Evaluating treatment<sup>13</sup></div>
                                                                            </div>
                                                                <div class="body">
                                                                    <div class="row">
                                                                            <div class="body no-heading">
                                            <ul>
<li>Evaluate effects on pain, function, mood and set goals</li>
<li>Use pain and function assessment scales,<sup>13 </sup>e.g. <a href="https://link.cep.health/cncpweb3" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">BPI</a>)</li>
<li>Consider trialing two or three drugs in succession from the same class if one is ineffective<sup>1</sup></li>
<li>Avoid co-prescribing two drugs from the same class</li>
<li>Due to safety risks associated with use of oral NSAIDs, use conservative dosing for the shortest possible duration consistent with approved prescribing limits<sup>14</sup></li>
<li>Regularly review ongoing value of each medication</li>
<li>If drug does not produce a meaningful improvement, stop or taper drug<sup>1</sup></li>
</ul>

                                                                                </div>
                                                                    </div>
                                                            </div>
                        </div>
                    </div>
            
                            </div>
        </div>
    </div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Options</h5>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">General non-opioid medications<sup>1</sup>:</h6>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Acetaminophen</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type<sup><br />
</sup></strong></span></p>
<ul>
<li><span style="font-size: 14px;">Osteoarthritis (hip or knee)</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span><br />
<span style="font-size: 14px;"><strong><br />
Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for hip or knee osteoarthritis (alone or in combination with NSAIDs), in addition to non-pharmacological treatments</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="gCNvVR">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="gCNvVR">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li>1000-4000 mg/day<sup>1</sup></li>
<li>Dose provided in product labelling (maximum 4000 mg/day) is for short term treatment (5 days)<sup>25</sup></li>
<li>There is greater risk (including gastrointestinal adverse events and multi-organ failure) from acetaminophen with extended duration of use, use conservative dosing and treatment duration<sup>26</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>Can be hepatotoxic at doses greater than 3-4 grams/ day and at lower dosages in patients with chronic alcohol use or liver disease<sup>2</sup></li>
<li>Consider liver function tests if hepatic risk (history of liver problems or alcohol abuse, long-term use)<sup>24</sup></li>
<li>Reduce dose in liver insufficiency or alcohol dependence<sup>2</sup></li>
<li>Many medications (e.g. over-the-counter cough and cold and pain relief products) contain acetaminophen; read the label and avoid exceeding maximum dose<sup>25</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Tapering not required</li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>43</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Nonsteroidal anti-inflammatory drugs (NSAIDs)</span>
                    <h6>Celecoxib</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for chronic nonspecific low back pain</span></li>
<li><span style="font-size: 14px;">May have synergistic, dose-sparing effect when added to opioids<sup>17</sup></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="Pr4Aeq">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="Pr4Aeq">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li>100 mg twice daily or 200 mg once daily (200 mg twice daily for rheumatoid arthritis, 200 mg/day for other type of pain)<sup>30</sup></li>
<li>Allow 1-2 weeks for full effect<sup>24</sup></li>
<li>Consider lower doses in the elderly<sup>29</sup></li>
<li>Swallow whole, take with food<sup>27,28,30,31</sup></li>
<li>Due to serious safety risks associated with oral NSAID use, use conservative dosing and treatment duration consistent with approved prescribing limits<sup>26</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>Risk of gastrointestinal bleeding/perforation, gastritis, and peptic ulcer disease<sup>2,17</sup></li>
<li>Causes fluid retention<sup>23</sup></li>
<li>Avoid in severe renal dysfunction (CrCl &lt; 30 mL/ min) or deteriorating renal disease; use caution if CrCl = 30-59 mL/min<sup>27,28</sup></li>
<li>Avoid in severe hepatic impairment</li>
<li>Avoid during pregnancy (3rd trimester) or breastfeeding, severe uncontrolled heart failure, severe allergy to acetylsalicylic acid or NSAIDs, active peptic ulcer disease, cerebrovascular disease, inflammatory bowel disease, or known hyperkalemia<sup>27</sup></li>
<li>Monitor blood pressure and signs of heart failure</li>
<li>Avoid in the elderly (consider topicals instead)<sup>17</sup></li>
<li>Cardiovascular risks (heart attack and stroke)<sup>2 </sup></li>
<li>Ibuprofen (but not other NSAIDs) interacts with acetylsalicylic acid to make it less effective for cardioprotection and stroke prevention<sup>12</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Tapering not required</li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>43</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Nonsteroidal anti-inflammatory drugs (NSAIDs)</span>
                    <h6>Diclofenac</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for chronic nonspecific low back pain</span></li>
<li><span style="font-size: 14px;">May have synergistic, dose-sparing effect when added to opioids<sup>20</sup></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="3v965H">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="3v965H">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p>Dosage:*</p>
<ul>
<li><span style="text-decoration: underline;">Diclofenac regular-release</span>: 75-100 mg daily (divided into 3 daily doses; max 100 mg/day)<sup>23</sup></li>
<li><span style="text-decoration: underline;">Diclofenac sustained release</span>: 75-100 mg once daily (max 100 mg/day)<sup>30</sup></li>
<li><span style="text-decoration: underline;">Diclofenac + misoprostol</span>: 50 mg (diclofenac) + 200 mg (misoprostol) bid (max dose same as starting dose)<sup>34</sup></li>
<li>Allow 1-2 weeks for full effect<sup>27</sup></li>
<li>Consider lower doses in the elderly<sup>32</sup></li>
<li>Swallow whole, take with food<sup>30,31,33,34</sup></li>
<li>Due to serious safety risks associated with oral NSAID use, use conservative dosing and treatment duration consistent with approved prescribing limits<sup>29</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>Risk of gastrointestinal bleeding/perforation, gastritis, and peptic ulcer disease<sup>2,20</sup></li>
<li>Causes fluid retention<sup>26</sup></li>
<li>Avoid in severe renal dysfunction (CrCl &lt; 30 mL/ min) or deteriorating renal disease; use caution if CrCl = 30-59 mL/min<sup>30,31</sup></li>
<li>Avoid in severe hepatic impairment</li>
<li>Avoid during pregnancy (3rd trimester) or breastfeeding, severe uncontrolled heart failure, severe allergy to acetylsalicylic acid or NSAIDs, active peptic ulcer disease, cerebrovascular disease, inflammatory bowel disease, or known hyperkalemia<sup>30</sup></li>
<li>Monitor blood pressure and signs of heart failure</li>
<li>Avoid in the elderly (consider topicals instead)<sup>20</sup></li>
<li>Cardiovascular risks (heart attack and stroke)<sup>2</sup></li>
<li>Ibuprofen (but not other NSAIDs) interacts with acetylsalicylic acid to make it less effective for cardioprotection and stroke prevention<sup>14</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Tapering not required</li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>46</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Nonsteroidal anti-inflammatory drugs (NSAIDs)</span>
                    <h6>Ibuprofen</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for chronic nonspecific low back pain</span></li>
<li><span style="font-size: 14px;">May have synergistic, dose-sparing effect when added to opioids<sup>17</sup></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="tKqUZf">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="tKqUZf">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li><span style="text-decoration: underline;">Ibuprofen regular-release formulation</span>: 200-400 mg q6-8h (max 1200 mg/day)<sup>32,33</sup></li>
<li><span style="text-decoration: underline;">Ibuprofen 12-hour formulation</span>: 600 mg q12h (max 1200 mg/day)<sup>32,33</sup></li>
<li>Allow 1-2 weeks for full effect<sup>24</sup></li>
<li>Consider lower doses in the elderly<sup>29</sup></li>
<li>Swallow whole, take with food<sup>27,28,30,31</sup></li>
<li>Due to serious safety risks associated with oral NSAID use, use conservative dosing and treatment duration consistent with approved prescribing limits<sup>26</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>Risk of gastrointestinal bleeding/perforation, gastritis, and peptic ulcer disease<sup>2,17</sup></li>
<li>Causes fluid retention<sup>23</sup></li>
<li>Avoid in severe renal dysfunction (CrCl &lt; 30 mL/ min) or deteriorating renal disease; use caution if CrCl = 30-59 mL/min<sup>27,28</sup></li>
<li>Avoid in severe hepatic impairment</li>
<li>Avoid during pregnancy (3rd trimester) or breastfeeding, severe uncontrolled heart failure, severe allergy to acetylsalicylic acid or NSAIDs, active peptic ulcer disease, cerebrovascular disease, inflammatory bowel disease, or known hyperkalemia<sup>27</sup></li>
<li>Monitor blood pressure and signs of heart failure</li>
<li>Avoid in the elderly (consider topicals instead)<sup>17</sup></li>
<li>Cardiovascular risks (heart attack and stroke)<sup>2 </sup></li>
<li>Ibuprofen (but not other NSAIDs) interacts with acetylsalicylic acid to make it less effective for cardioprotection and stroke prevention<sup>12</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Tapering not required</li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>43</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Nonsteroidal anti-inflammatory drugs (NSAIDs)</span>
                    <h6>Meloxicam</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
</ul>
<p><strong style="font-size: 14px;">Level of evidence<br />
</strong><span style="font-size: 14px;"><strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for chronic nonspecific low back pain.</span></li>
<li><span style="font-size: 14px;">May have synergistic, dose-sparing effect when added to opioids<sup>17</sup></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="qmR6FC">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="qmR6FC">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li>7.5-15 mg daily (max 15mg/ day)<sup>34</sup></li>
<li>Allow 1-2 weeks for full effect<sup>24</sup></li>
<li>Consider lower doses in the elderly<sup>29</sup></li>
<li>Swallow whole, take with food<sup>27,28,30,31</sup></li>
<li>Due to serious safety risks associated with oral NSAID use, use conservative dosing and treatment duration consistent with approved prescribing limits<sup>26</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>Risk of gastrointestinal bleeding/perforation, gastritis, and peptic ulcer disease<sup>2,17</sup></li>
<li>Causes fluid retention<sup>23</sup></li>
<li>Avoid in severe renal dysfunction (CrCl &lt; 30 mL/ min) or deteriorating renal disease; use caution if CrCl = 30-59 mL/min<sup>27,28</sup></li>
<li>Avoid in severe hepatic impairment</li>
<li>Avoid during pregnancy (3rd trimester) or breastfeeding, severe uncontrolled heart failure, severe allergy to acetylsalicylic acid or NSAIDs, active peptic ulcer disease, cerebrovascular disease, inflammatory bowel disease, or known hyperkalemia<sup>27</sup></li>
<li>Monitor blood pressure and signs of heart failure</li>
<li>Avoid in the elderly (consider topicals instead)<sup>17</sup></li>
<li>Cardiovascular risks (heart attack and stroke)<sup>2 </sup></li>
<li>Ibuprofen (but not other NSAIDs) interacts with acetylsalicylic acid to make it less effective for cardioprotection and stroke prevention<sup>12</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Tapering not required</li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>43</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Nonsteroidal anti-inflammatory drugs (NSAIDs)</span>
                    <h6>Naproxen</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for chronic nonspecific low back pain.</span></li>
<li><span style="font-size: 14px;">May have synergistic, dose-sparing effect when added to opioids<sup>17</sup></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="pYcXxi">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="pYcXxi">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li><span style="text-decoration: underline;">220 mg strength</span>: 220 mg q 8-12h (max 440 mg/day)<sup>28</sup></li>
<li><span style="text-decoration: underline;">125, 250, 375, and 500 mg strengths</span>: starting dose 250 mg bid may be increased to 375-500 mg bid; usual max = 1000 mg/day (may be increased to 1500 mg/day for limited periods with careful monitoring)<sup>35</sup></li>
<li><span style="text-decoration: underline;">275 and 550 mg strengths</span>: 275 mg q6-8h (max 1375 mg/day) or 550 mg bid<sup>66</sup></li>
<li><span style="text-decoration: underline;">750 mg sustained-release strength</span>: 750 mg once daily (max 750 mg/day)<sup>35</sup></li>
<li>Allow 1-2 weeks for full effect<sup>24</sup></li>
<li>Consider lower doses in the elderly<sup>29</sup></li>
<li>Swallow whole, take with food<sup>27,28,30,31</sup></li>
<li>Due to serious safety risks associated with oral NSAID use, use conservative dosing and treatment duration consistent with approved prescribing limits<sup>26</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>Risk of gastrointestinal bleeding/perforation, gastritis, and peptic ulcer disease<sup>2,17</sup></li>
<li>Causes fluid retention<sup>23</sup></li>
<li>Avoid in severe renal dysfunction (CrCl &lt; 30 mL/ min) or deteriorating renal disease; use caution if CrCl = 30-59 mL/min<sup>27,28</sup></li>
<li>Avoid in severe hepatic impairment</li>
<li>Avoid during pregnancy (3rd trimester) or breastfeeding, severe uncontrolled heart failure, severe allergy to acetylsalicylic acid or NSAIDs, active peptic ulcer disease, cerebrovascular disease, inflammatory bowel disease, or known hyperkalemia<sup>27</sup></li>
<li>Monitor blood pressure and signs of heart failure</li>
<li>Avoid in the elderly (consider topicals instead)<sup>17</sup></li>
<li>Cardiovascular risks (heart attack and stroke)<sup>2 </sup></li>
<li>Ibuprofen (but not other NSAIDs) interacts with acetylsalicylic acid to make it less effective for cardioprotection and stroke prevention<sup>12</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Tapering not required</li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>43</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Anticonvulsants<sup>1</sup> and <strong>antidepressants</strong><sup>1</sup><strong>:</strong></h6>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="is-style-red-background"><strong>Anticonvulsants with insufficient evidence to support use in chronic pain:<sup>1</sup>&nbsp;</strong> Sodium valproate, lacosamide, lamotrigine, phenytoin, clonazepam, levetiracetam, topiramate</p>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Carbamazepine</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Trigeminal neuralgia (may also be used for general neuropathic pain)</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for neuropathic pain</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="Yu5RzM">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="Yu5RzM">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li><span style="text-decoration: underline;">Initiation</span>: 100 mg – 200 mg daily</li>
<li><span style="text-decoration: underline;">Titration</span>: increase biweekly by 100-200 mg/ day</li>
<li><span style="text-decoration: underline;">Usual maintenance dose</span>: 200- 800 mg per day (in 2 to 4 divided doses)</li>
<li>Doses of up to 1200-1600 mg/ day have been used<sup>1,36</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>May cause blood dyscrasias and liver toxicity<sup>17 </sup></li>
<li>Monitor blood counts and liver function tests<sup>27</sup></li>
<li>Enzyme inducer – may interfere with other drugs such as warfarin<sup>1</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Every 3 months, consider discontinuing or reducing the dose<sup>36</sup></li>
<li>Requires tapering: reduce dose by approximately 20% each week (faster if patient has reduced liver function)<sup>37</sup></li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>43</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Gabapentin</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Neuropathic pain</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered (at doses titrated up to at least 1,200 mg/day) for neuropathic pain</span></li>
<li><span style="font-size: 14px;">Generally 1st line gabapentinoid</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="NKKckr">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="NKKckr">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li><span style="text-decoration: underline;">Initiation</span>: 300 mg once daily at night</li>
<li><span style="text-decoration: underline;">Titration</span>: Increase weekly by 300 mg/day</li>
<li><span style="text-decoration: underline;">Usual maintenance dose</span>: 1,200- 3,600 mg/day (divided into 3 doses)<sup>1</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>May cause dizziness, drowsiness, or confusion<sup>24,17</sup></li>
<li>Potential for abuse could lead to drug misuse or make the patient a target for drug abusers<sup>29</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Requires tapering: reduce dose gradually over at least 1 week<sup>38,39</sup></li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>43</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Pregabalin</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type<sup>1</sup></strong></span></p>
<ul>
<li><span style="font-size: 14px;">Neuropathic pain</span></li>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;"><span style="text-decoration: underline;">Neuropathic pain</span>: should be considered (at doses titrated up to at least 300 mg/day) for neuropathic pain if other 1st and 2nd line pharmacological treatments have failed</span></li>
<li><span style="font-size: 14px;"><span style="text-decoration: underline;">Fibromyalgia</span>: is recommended (at doses titrated up to at least 300 mg/day) for fibromyalgia</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="qAnj2Y">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="qAnj2Y">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li><span style="text-decoration: underline;">Initiation</span>: 75 mg twice daily</li>
<li><span style="text-decoration: underline;">Usual maintenance dose</span>: 300 mg/ day (150 mg bid)</li>
<li><span style="text-decoration: underline;">Maximum</span>: 600 mg/day (300 mg bid)<sup>2</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>May cause sedation or dizziness<sup>8</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Reduce dose gradually over at least 1 week<sup>22</sup></li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>43</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Tricyclic Antidepressants (TCAs)</span>
                    <h6>Amitriptyline, Nortriptyline, Imipramine</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Neuropathic pain</span></li>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for neuropathic pain, except HIV-related neuropathic pain (imipramine or nortriptyline may be used if amitriptyline is ineffective)</span></li>
<li><span style="font-size: 14px;">Should be considered for fibromyalgia</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="lI2bw1">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="lI2bw1">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong>*</p>
<ul>
<li><span style="text-decoration: underline;">Amitriptyline</span>: Starting dose 10-25 mg/day; titration: increase weekly by 10 mg/day; usual maintenance dose: 25-125 mg/day<sup>1</sup></li>
<li><span style="text-decoration: underline;">Imipramine or nortriptyline</span>: 25-75 mg/day<sup>1</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>May cause sedation, dry mouth, confusion, constipation, urinary retention, prolonged QT interval, weight gain<sup>24,17</sup></li>
<li>Many side effects may be tolerable with patient education, gradual dose titration and allowance for 1-2 weeks at a steady dose</li>
<li>Caution in elderly (nortriptyline preferred)<sup>17</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Taper gradually over 4 weeks to 3 months or more (e.g. reduce dose by 25% every 4 weeks)<sup>41</sup> particularly if patient has been on the drug for 6 weeks or more</li>
<li>Doses should be decreased more slowly towards the end of the Taper<sup>42-53,16</sup></li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>43</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Serotonin Norepinephrine Reuptake Inhibitor (SNRI)</span>
                    <h6>Duloxetine</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Neuropathic pain due to diabetes</span></li>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for diabetic neuropathic pain if other 1st or 2nd line pharmacological therapies have failed</span></li>
<li><span style="font-size: 14px;">Should be considered for fibromyalgia</span></li>
<li><span style="font-size: 14px;">Should be considered for osteoarthritis</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="LPLiMv">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="LPLiMv">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li>Starting dose: 60 mg once daily (30 mg starting dose may be used for tolerability reasons in some patients, with a goal of reaching 60 mg once daily within 1-2 weeks)<sup>45</sup>; <span style="font-size: 14px;">Usual maintenance dose: 60 mg once daily (doses of up to 120 mg/ day have been used)<sup>1</sup></span></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>May cause headache, gastrointestinal upset, insomnia, drowsiness, constipation, fatigue, dizziness<sup>17</sup></li>
<li>Contraindicated in hepatic or severe renal impairment<sup>45</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Requires tapering if patient has been taking for more than 1 week<sup>45</sup></li>
<li>Taper by switching to 30 mg strength or taking 60 mg on alternate days for at least 2 weeks<sup>46</sup></li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>43</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Serotonin Reuptake Inhibitor (SSRI)</span>
                    <h6>Fluoxetine</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Fibromyalgia</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for fibromyalgia</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="z7rIof">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="z7rIof">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li>20 mg/day (up to 80 mg/day)<sup>1</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>May cause nausea, dizziness, headache, anxiety, nervousness, drowsiness, weakness, diarrhea, upset stomach, dry mouth, loss of appetite, excessive sweating, sexual dysfunction</li>
<li>May cause aggression or suicidal ideation/ behaviour</li>
<li>May prolong QT<sup>47</sup></li>
</ul>
<p><strong>Tapering**</strong></p>
<ul>
<li>Tapering generally not required (fluoxetine has a low risk of withdrawal symptoms due to its long half-life; active drug substances persist in the body for weeks)<sup>42,47</sup></li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
<p><span style="font-size: 12px;"><em>** Tapering recommendations are intended as general guidelines only. Monitor the patient’s response to dosage changes and use clinical judgment to base the pace of the taper on the patient’s response to prior dosage reductions.<sup>43</sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Topicals<sup>1</sup> and <strong>medical cannabinoids</strong>:</h6>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="has-text-align-left is-style-red-background"><strong>Cannabinoids are not equivalent in effectiveness to anti-depressants or anti-convulsants.<sup>16</sup> </strong><br><strong>Cannabinoid forms can be considered for neuropathic pain.<sup>16</sup></strong></p>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">Nonsteroidal anti-inflammatory drugs (NSAIDs)</span>
                    <h6>Diclofenac solution<sup>48</sup> or gel<sup>49</sup></h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Musculoskeletal pain<sup>1</sup></span></li>
<li><span style="font-size: 14px;">Osteoarthritis<sup>50</sup></span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for musculoskeletal pain<sup>1</sup> or osteoarthritis<sup>50</sup>, in patients who cannot tolerate oral NSAIDs</span></li>
<li><span style="font-size: 14px;">Manufactured and compounded NSAID products may vary in potency</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="mFNIcM">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="mFNIcM">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li><span style="text-decoration: underline;">Solution</span>: 50 drops per knee 3 times a day, or 40 drops per knee 4 times a day<sup>46</sup></li>
<li><span style="text-decoration: underline;">Gel</span>: Apply 3-4 times daily (for lower strengths) or twice daily (for higher strengths)<sup>49</sup></li>
<li>Allow 1 week to reach full effects<sup>24</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>Do not apply to skin with cuts or rashes</li>
<li>May cause skin blistering</li>
<li>Increases sun sensitivity (rare)<sup>49</sup></li>
</ul>
<p><strong>Tapering</strong></p>
<ul>
<li class="p1">Tapering is not required for topical medications</li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Salicylate-Containing Rubifacients</span>
                    <h6>Triethanolamine Salicylate</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Musculoskeletal pain</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><br />
<strong>•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered for musculoskeletal pain if other pharmacological therapies have been ineffective</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="K54TWc">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="K54TWc">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage*</strong></p>
<ul>
<li>1 to 3 plasters (12 hours on, 12 hours off)</li>
<li>Try for up to 4 weeks, then discontinue if no improvement</li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>Skin reddening and irritation at application site</li>
</ul>
<p><strong>Tapering</strong></p>
<ul>
<li class="p1">Tapering is not required for topical medications</li>
</ul>
<p>&nbsp;</p>
<p><span style="font-size: 12px;"><em>* Titrate until efficacy or intolerance.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">26, 17</a></sup> Counsel that side effects often diminish after 1-2 weeks.<sup><a href="https://tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">24</a></sup></em></span></p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Synthetic tetrahydrocannabinol</span>
                    <h6>Nabilone-Oral</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Neuropathic pain<sup>16</sup></span></li>
</ul>
<p><strong style="font-size: 14px;">Level of evidence</strong></p>
<ul>
<li><span style="font-size: 14px;">Evidence is weaker than for other drug treatments<sup>16</sup></span></li>
<li><span style="font-size: 14px;">No research evidence to support use in other types of chronic pain (fibromyalgia, low back pain, osteoarthritis); only for neuropathic pain that has failed to respond to standard treatments<sup>16</sup></span></li>
</ul>
<p><strong style="font-size: 14px;">Role in therapy</strong></p>
<ul>
<li><span style="font-size: 14px;">In general, other pharmacological and nonpharmacological neuropathic pain therapies should be tried first</span></li>
<li><span style="font-size: 14px;">Long-term benefits and harms in chronic non-cancer pain not well studied<sup>16,52,53</sup></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="MD0TzF">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="MD0TzF">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong></p>
<ul>
<li>1 or 2 mg bid; max 6 mg/day<sup>53</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>May cause drowsiness, euphoria, dry mouth, hallucinations</li>
<li>Even low doses of cannabis can cause cognitive impairment lasting up to 24 hours<sup>16</sup></li>
<li>May cause physical or psychological dependence<sup>52</sup></li>
<li>Dried cannabis is not appropriate for people:
<ul>
<li>under 25 years of age</li>
<li>with personal or strong family history of psychosis</li>
<li>with current or past cannabis use disorder</li>
<li>with cardiovascular disease</li>
<li>who are pregnant, planning to become pregnant, or breastfeeding<sup>16</sup></li>
</ul>
</li>
<li>Caution (for oral cannabis) in liver dysfunction<sup>53</sup></li>
</ul>
<p><strong>Tapering</strong></p>
<ul>
<li>Data not available on tapering<sup>16</sup></li>
<li>If patients using cannabinoids are also on high doses of benzodiazepines or opioids, consider lowering the dose of these medications<sup>16</sup></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Buccal Cannabinoids<sup>1,52</sup></span>
                    <h6>Nabiximols</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Neuropathic pain<sup>16</sup></span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Evidence is weaker than for other drug treatments<sup>16</sup></span></li>
<li><span style="font-size: 14px;">No research evidence to support use in other types of chronic pain (fibromyalgia, low back pain, osteoarthritis); only for neuropathic pain that has failed to respond to standard treatments<sup>16</sup></span></li>
</ul>
<p><strong style="font-size: 14px;">Role in therapy</strong></p>
<ul>
<li><span style="font-size: 14px;">In general, other pharmacological and nonpharmacological neuropathic pain therapies should be tried first</span></li>
<li><span style="font-size: 14px;">Nabiximols are indicated as adjunctive treatment for neuropathic pain in patients with multiple sclerosis<sup>52</sup></span></li>
<li><span style="font-size: 14px;">Long-term benefits and harms in chronic non-cancer pain not well studied<sup>16,52,53</sup></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="yS7YM4">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="yS7YM4">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong></p>
<ul>
<li>4 to 8 sprays/day (divided bid); max 12 sprays/day<sup>52</sup></li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>May cause drowsiness, euphoria, dry mouth, hallucinations</li>
<li>Even low doses of cannabis can cause cognitive impairment lasting up to 24 hours<sup>16</sup></li>
<li>May cause physical or psychological dependence<sup>52</sup></li>
<li>Dried cannabis is not appropriate for people:
<ul>
<li>under 25 years of age</li>
<li>with personal or strong family history of psychosis</li>
<li>with current or past cannabis use disorder</li>
<li>with cardiovascular disease</li>
<li>who are pregnant, planning to become pregnant, or breastfeeding<sup>16</sup></li>
</ul>
</li>
<li>Caution (for oral cannabis) in liver dysfunction<sup>53</sup></li>
</ul>
<p><strong>Tapering</strong></p>
<ul>
<li>Data not available on tapering<sup>18</sup></li>
<li>If patients using cannabinoids are also on high doses of benzodiazepines or opioids, consider lowering the dose of these medications<sup>18</sup></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Vaporizer or edible product</span>
                    <h6>Dried cannabis </h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Neuropathic pain<sup>16</sup></span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong></span></p>
<ul>
<li><span style="font-size: 14px;">Evidence is weaker than for other drug treatments<sup>16</sup></span></li>
<li><span style="font-size: 14px;">No research evidence to support use in other types of chronic pain (fibromyalgia, low back pain, osteoarthritis); only for neuropathic pain that has failed to respond to standard treatments<sup>16</sup></span></li>
</ul>
<p><strong style="font-size: 14px;">Role in therapy</strong></p>
<ul>
<li><span style="font-size: 14px;">In general, other pharmacological and nonpharmacological neuropathic pain therapies should be tried first</span></li>
<li><span style="font-size: 14px;">Do not use for neuropathic pain unless other pharmacologic therapies, nonpharmacologic therapies, and oral cannabinoids have failed<sup>16</sup></span></li>
<li><span style="font-size: 14px;">Long-term benefits and harms in chronic non-cancer pain not well studied<sup>16,52,53</sup></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="ccLwqL">View Dosage, Potential Harms &#038; More</a>
                                      </div>
                                      <div class="modal" data-modal="ccLwqL">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong></p>
<ul>
<li>Dose is difficult to standardize due to limited dosing studies, differences in administration and cannabinoid content of different strains of cannabis, as well as interpatient variability.</li>
<li>One study of vaporized cannabis used 800 mg placed in the vaporizer, with 8 to 12 inhalations taken over 2 hours. Inhale slowly over 5 seconds, hold breath for 10 seconds, then gently exhale.</li>
<li>For smoked cannabis (note: vaporization is generally preferred to smoking for safety reasons), the dose may range from 100-700 mg of no more than 9% THC cannabis daily. The upper safe level is approximately 3.0 g of dried cannabis per day (this upper limit would only be used for experienced cannabis users, not naïve patients, and would be gradually reached).<sup>16</sup></li>
<li>There is some evidence for dry cannabis use with the bulk of the information on vaporized and smoked. Very little evidence exists in edible products. The upper safe limit is 3.0 g (this would only be used for experienced cannabis users).</li>
</ul>
<p><strong>Potential harms</strong></p>
<ul>
<li>May cause drowsiness, euphoria, dry mouth, hallucinations</li>
<li>Even low doses of cannabis can cause cognitive impairment lasting up to 24 hours<sup>16</sup></li>
<li>May cause physical or psychological dependence<sup>52</sup></li>
<li>Dried cannabis is not appropriate for people:
<ul>
<li>under 25 years of age</li>
<li>with personal or strong family history of psychosis</li>
<li>with current or past cannabis use disorder</li>
<li>with cardiovascular disease</li>
<li>who are pregnant, planning to become pregnant, or breastfeeding<sup>16</sup></li>
</ul>
</li>
<li>Caution (for oral cannabis) in liver dysfunction<sup>53</sup></li>
</ul>
<p><strong>Tapering</strong></p>
<ul>
<li>Data not available on tapering<sup>16</sup></li>
<li>If patients using cannabinoids are also on high doses of benzodiazepines or opioids, consider lowering the dose of these medications<sup>16</sup></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px"><em>LEGEND: CATEGORIES FOR LEVELS OF EVIDENCE (according to original guidelines’ taxonomy)<br><strong>•••</strong>   Highest level of evidence (meta-analyses; systematic reviews of RCTs; RCTs with varying levels of bias)&nbsp;<br><strong>••    </strong>Mid-level evidence (systematic reviews of case studies; high quality case control or cohort studies; experimental studies w/o randomization; case reports or studies)<br><strong>•</strong>     Low-level evidence (expert opinion and/or clinical experiences of respected authorities/guideline development group)&nbsp; </em></p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Resources</h5>
</div></article>

<article class="block--support-materials ">
  <div class="container two-column">
    <div class="columns is-variable is-8">

      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">For providers</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://link.cep.health/cncpweb1" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Resources in your LHIN</a></li>
<li><a href="https://link.cep.health/cncpweb39" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Appendix B: for details on evidence, benefits/harms, and dosing</a></li>
</ul>
        </div>
      </div>
  
      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">For patients</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://www.tools.cep.health/wp-content/uploads/2020/03/CNCP-PT-resource-for-web-2020.03.30.pdf" data-wpel-link="internal">Printable patient handout with resources on information on pain, non-pharmacological therapies, opioids, support groups and self-management programs</a></li>
<li><a href="https://link.cep.health/cncpweb24" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">RNAO Fact sheets: Helping people manage their pain</a></li>
<li><a href="https://link.cep.health/cncpweb26" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Understanding Pain in less than 5 minutes, and what to do about it!</a></li>
<li><a href="https://link.cep.health/cncpweb28" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">People in Pain Network</a></li>
<li><a href="https://link.cep.health/cncpweb31" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Fact Sheet: Chronic Pain</a></li>
<li><a href="https://link.cep.health/cncpweb34" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Canadian Mental Health Association (CMHA)</a></li>
</ul>
        </div>
      </div>

    </div>
  </div>
</article>						</div>
					</div>
				</section>
							<section class="main-section" id="opioid-medications" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Opioid medications								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Yellow-Notice.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <div class="columns is-flex is-gapless">
<div class="column is-10-mobile is-11">
<p><strong>Opioid medications are not the preferred treatment for CNCP but may be considered in selected patients.</strong> If opioids are used, they should be combined with non-pharmacological treatments and non-opioid medications as appropriate.<sup>2</sup></p>
</div>
</div>
<div class="columns is-flex is-gapless">
<div class="column is-2-mobile is-1"></div>
</div>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Yellow-Notice.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <div id="block-fed5f73c-b645-4e10-9f40-a0485eff33bf" class="wp-block editor-block-list__block block-editor-block-list__block is-selected" tabindex="0" data-type="acf/text-with-icon" aria-label="Block: Text with Icon">
<div class="editor-block-list__block-edit block-editor-block-list__block-edit">
<div data-block="fed5f73c-b645-4e10-9f40-a0485eff33bf">
<div class="acf-block-component acf-block-body">
<div>
<div class="acf-block-preview">
<article class="block--text-with-icon ">
<div class="container">
<div class="columns is-flex is-gapless">
<div class="column is-10-mobile is-11">
<p>Before trying opioids, it is not necessary to sequentially “fail” non-pharmacological or non-opioid pharmacological therapies, though it is important to weigh expected benefits and risks of therapy.<sup>2</sup> <strong>There is no high quality evidence showing that opioids improve pain or function with long-term use.</strong></p>
</div>
</div>
</div>
</article>
</div>
</div>
</div>
</div>
</div>
</div>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Yellow-Notice.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p><strong>Naloxone: </strong>Advise patients with an opioid prescription to obtain a take-home naloxone kit. Ontarians with a health card are eligible for a free take-home naloxone kit from pharmacies, community organizations and provincial correctional facilities.<sup>2</sup></p>
          </div>
        </div>

      </div>
</article>

<article class="block--modal ">

<div class="outer">
  <div class="container">
    <div class="inner has-text-centered">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/talking-points.svg" alt="" />
                    <h6>If the patient wants opioids but they are not clinically appropriate try the Elicit-Provide-Elicit technique</h6>
                          <a data-modal="lyLaIY" class="button open-modal" href="#" data-id="lyLaIY">Click for Talking Points</a>
          </div>
  </div>
</div>

  <div data-modal="lyLaIY" class="modal">
    <div class="inner text">
      <div class="close-wrapper">
                <a href="" class="close" data-wpel-link="internal">Close</a>
      </div>
      <div class="container">
                <div class="content">
          
                                      <h6>The Elicit-Provide-Elicit technique</h6>
<p><strong>Elicit how patient feels they would benefit from an opioid: </strong><span style="font-size: 1.5rem;"> “You mentioned you would like to try an opioid. How are you hoping it will help you?”</span></p>
<p><strong>Provide information: </strong><span style="font-size: 1.5rem;">“If it’s all right, I can give you more information about opioids and how they work for pain. </span><strong style="font-size: 1.5rem;">Opioids may seem like they are very strong and effective drugs for pain; however, they are not effective for all types of pain.</strong><span style="font-size: 1.5rem;"> When opioids are effective, your pain may be reduced by about 1 or 2 points on a scale from 0 to 10 and you may notice a small improvement in your ability to function.</span><sup>1</sup><span style="font-size: 1.5rem;"> They also come with risks, and sometimes this means that opioids are not a safe and effective approach for pain relief. We may find that other approaches and medications could work better for you.”</span><sup><a href="https://www.tools.cep.health/tool/management-of-chronic-non-cancer-pain/?preview_id=41&amp;preview_nonce=9d576fdadb&amp;preview=true#references" data-wpel-link="internal">3</a></sup></p>
<p><strong>Elicit the patient’s thoughts: </strong>“How do you feel about trying some non-opioid options? What do you think makes sense for you right now?”</p>
            
                  </div>
      </div>
    </div>
    <div class="overlay"></div>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Recommendations*</h5>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>Opioids should be reserved for patients that meet the following criteria:</p>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Non-opioid treatments have been trialled or are being trialled concurrently;</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Pain is severe enough to interfere with daily function; and</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Patient is at a low risk of Opioid Use Disorder.</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Eye.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Use the <a href="https://link.cep.health/cncpweb6" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid Risk Tool</a> to gauge potential risk.<sup><a href="https://www.tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">2,5</a></sup> Supplement with a history identifying high risk factors such as current anxiety, depression, PTSD and/or current or past history of problematic substance use (e.g. alcohol, opioids, cannabis). Patients with a high risk/active Substance Use Disorder may require further consultation with an addictions expert.</p>
          </div>
        </div>

      </div>
</article>

<article class="block--table ">
<div class="container">
  <div class="table  inner-border-blue ">

                    <header>
                <h6>Opioid Use Disorder (OUD)<sup>5</sup></h6>
            </header>
        
                    <div class="rows">

                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:33%;">
                                            <h6>Clinical features of OUD</h6>
<ul>
<li><strong>Altering the route of delivery</strong>: injecting, biting or crushing oral formulations</li>
<li><strong>Accessing opioids from other sources</strong>: taking the drug from friends or relatives; purchasing the drug from the ‘street’; double-doctoring</li>
<li><strong>Unsanctioned use</strong>: multiple unauthorized dose escalations; binge use rather than scheduled use</li>
<li><strong>Drug seeking</strong>: recurrent prescription losses; aggressive complaining about the need for higher doses; harassing medical office staff for faxed scripts or ‘fit-in’ appointments; nothing else ‘works’</li>
<li><strong>Repeated withdrawal symptoms</strong>: marked dysphoria, myalgia, gastrointestinal symptoms, cravings</li>
<li><strong>Accompanying conditions</strong>: Currently addicted to alcohol, cocaine, cannabis, or other drugs; underlying mood or anxiety disorders are not responsive to treatment</li>
<li><strong>Social features</strong>: Deteriorating or poor social function; concern expressed by family members</li>
<li><strong>Views on the opioid medication</strong>: Sometimes acknowledges being addicted; strong resistance to tapering or switching opioids; may admit to mood-leveling effect; may acknowledge distressing withdrawal symptoms</li>
</ul>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:33%;">
                                            <h6>Strategies to prevent OUD</h6>
<ul>
<li>Identify high risk patients: individuals with current anxiety, depression, PTSD; individuals with current or past history of problematic alcohol or drug use.</li>
<li>Do not prescribe opioids to patients at high risk for OUD unless they have a biomedical pain condition affecting function, and have failed at all first-line non opioid treatments. Do not prescribe for fibromyalgia or simple low back pain.</li>
<li>Take a baseline urine drug sample. Do not prescribe opioids if cocaine or non-authorized drugs are present.</li>
<li>Dispense small amounts frequently – weekly, twice weekly, daily if necessary; especially if patient runs out early.</li>
<li>Set the maintenance dose at the lowest possible dose – in most cases, it should be no more than 50 MME.</li>
<li>Avoid any drug that is commonly misused in the community (e.g. hydromorphone, fentanyl, oxycodone).</li>
<li>If patient shows clinical features of OUD, consider management with buprenorphine or methadone, or specialized addiction clinic referral if appropriate.</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                
            </div>
        
                    <footer>
                <p><strong>Note: <em>Continuing to prescribe opioids in the face of opioid addiction may put the patient at risk of harm. However, stopping or refusing to prescribe opioids can also cause harm, such as severe withdrawal symptoms or driving the patient to obtain opioids from the street. It is important to mitigate these risks by finding a safe way to reduce and manage opioid use.</em></strong></p>
            </footer>
        
    </div>
</div>
</article>

<article class="block--multiple-choices ">
<div class="container">
    <div class="columns">
        <div class="column text">
            <div class="inner">
                                    <h6><img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/multiple-choices.svg" alt="Stack of papers." /> Click for tips on</h6>
                                            </div>
        </div>
    </div>
            <div class="columns">
            <div class="column choice-buttons">
                
                        
                        <button data-choice-button="1" class="green">Initiating opioids<sup>1,3</sup></button>
                        
                
                        
                        <button data-choice-button="2" class="green">Titrating opioids<sup>1,3</sup></button>
                        
                
                        
                        <button data-choice-button="3" class="green">Evaluating opioids<sup>13</sup></button>
                        
                
                        
                        <button data-choice-button="4" class="green">Tapering opioids</button>
                        
                            </div>
        </div>

        <div class="columns">
            <div class="column choice-content-wrapper">
                
                        
                        <div data-choice-content="1" class="choice-content">
                            <div class="table ">
                                                                    <div class="header">
                                                                                    <div class="heading">Initiating opioids<sup>1,3</sup></div>
                                                                            </div>
                                                                <div class="body">
                                                                    <div class="row">
                                                                            <div class="body no-heading">
                                            <ul>
<li>Set goals with patient (pain reduction, improved function/mood)</li>
<li>Discuss the short-term benefits and potential side effects/risks, such as potential loss of efficacy over time</li>
<li>Use the lowest effective dose – aim to keep the dose under 90 MME. If a larger dose is required, consider obtaining a second opinion<sup>2,3</sup></li>
<li>Avoid prescription of sedative and hypnotic medication when possible</li>
<li>Benzodiazepines can considerably lower the lethal opioid dose; consider tapering off of benzodiazepines or starting with a lower dose of opioid</li>
<li>Be aware of concomitant use of alcohol and over the counter medications</li>
<li>Parenteral opioids are not recommended in CNCP (high risk of overdose, addiction, and infection)</li>
<li>Use caution with controlled-release formulations: they can cause overdose if bitten/crushed (this converts them to immediate-release)<sup>13</sup></li>
<li>Agree on duration of an opioid trial (e.g. typically 2 weeks at optimal dose)</li>
<li>For patients on opioids over 90 morphine milligram equivalents (MME) or patients on opioids with a potential risk for overdose (i.e. past/active/evolving Opioid Use Disorder or concurrent benzodiazepine use), encourage the patient to obtain take home naloxone (kit or intranasal spray) from their pharmacist<sup>2</sup></li>
<li>Before starting opioids, discuss an “exit strategy” for how opioids will be discontinued if they do not produce benefits that outweigh risks<sup>2</sup></li>
</ul>

                                                                                </div>
                                                                    </div>
                                                            </div>
                        </div>
                    </div>
            
                
                        
                        <div data-choice-content="2" class="choice-content">
                            <div class="table ">
                                                                    <div class="header">
                                                                                    <div class="heading">Titrating opioids<sup>1,3</sup></div>
                                                                            </div>
                                                                <div class="body">
                                                                    <div class="row">
                                                                            <div class="body no-heading">
                                            <ul>
<li>Monitor every 2-4 weeks</li>
<li>Do a 3-day “tolerance check” for those at high risk of sedation (elderly, on benzodiazepines, renal or hepatic impairment, COPD, sleep disorders, cognitive impairment).<sup><span class="s1">8 </span></sup>Call the patient 3 days after initiation or dose change to ask about signs of sedation<sup><span class="s1">3</span></sup></li>
<li>Titrate oral opioids until efficacious* (an improvement in function and/or pain of 2 points on a 10-point scale)<sup>3,17</sup></li>
<li>Benzodiazepines can considerably lower the lethal opioid dose; consider tapering off of benzodiazepines or starting with a lower dose of opioid</li>
<li>Parenteral opioids are not recommended in CNCP (high risk of overdose, addiction, and infection)</li>
<li>Use caution with controlled-release formulations: they can cause overdose if bitten/crushed (this converts them to immediate-release)<sup>13 </sup></li>
<li>Most patients respond to doses in the range of 0-50 MME. As the dose increases, the risk of overdose, addiction, falls, motor vehicle accidents and sleep apnea increase as well</li>
<li>Use the lowest effective dose – aim to keep the dose under 90 MME. If a larger dose is required, consider obtaining a second opinion<sup>2,3</sup></li>
<li>Opioids have a medium effect on pain (10-20% reduction) and a small effect on function (&lt;10% change): function can improve even when pain is still present<sup> 2,3</sup></li>
</ul>

                                                                                </div>
                                                                    </div>
                                                            </div>
                        </div>
                    </div>
            
                
                        
                        <div data-choice-content="3" class="choice-content">
                            <div class="table ">
                                                                    <div class="header">
                                                                                    <div class="heading">Evaluating opioids<sup>13</sup></div>
                                                                            </div>
                                                                <div class="body">
                                                                    <div class="row">
                                                                            <div class="body no-heading">
                                            <ul>
<li>For conditions where opioids may be effective, establish realistic expectations:<sup>2</sup>
<ul>
<li>After titration, evaluate benefits and risks of continued therapy at least every 3 months<sup><a href="https://www.tools.cep.health/tool/management-of-chronic-non-cancer-pain/#references" data-wpel-link="internal">2</a></sup></li>
<li>If drug does not produce a meaningful improvement, discontinue/taper</li>
<li>If opioids are inappropriately used, the risk of overdose, hypogonadism, sleep disorders or respiratory function can worsen</li>
</ul>
</li>
</ul>

                                                                                </div>
                                                                    </div>
                                                            </div>
                        </div>
                    </div>
            
                
                        
                        <div data-choice-content="4" class="choice-content">
                            <div class="table ">
                                                                    <div class="header">
                                                                                    <div class="heading">Tapering opioids</div>
                                                                            </div>
                                                                <div class="body">
                                                                    <div class="row">
                                    
                                        <div class="heading">
                                            Indications to taper and discontinue opioids                                        </div>
                                                                                <div class="body ">
                                            <ul>
<li>Insufficient analgesia, insufficient effect on function, or a failed opioid trial</li>
<li>Significant side effects (e.g. sedation, fatigue, depression, sleep apnea, falls, motor vehicle accidents, testosterone suppression)</li>
<li>Suspected Opioid Use Disorder</li>
<li>High opioid dose (well above 90 MME), even if no obvious side effects are present</li>
</ul>

                                                                                </div>
                                    
                                        <div class="heading">
                                            How to taper<sup>5</sup>                                        </div>
                                                                                <div class="body ">
                                            <ul>
<li>Explain to the patient that tapering often improves pain, mood and function</li>
<li>Opioids should never be abruptly stopped, as it may trigger unauthorized use and is an increased risk for overdose</li>
<li>There are many protocols for an opioid taper. For examples of opioid tapers see the <a href="https://link.cep.health/cncpweb7" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid Tapering Template</a></li>
</ul>

                                                                                </div>
                                    
                                        <div class="heading">
                                            Tapering pearls                                        </div>
                                                                                <div class="body ">
                                            <ul>
<li>In patients who have been on opioids for years a slower taper is more likely to be successful</li>
<li>Taper more cautiously during pregnancy and/or seek out expert consultation – acute withdrawal increases the risk of premature labour and spontaneous abortion</li>
<li>Avoid sedative-hypnotic medications, especially benzodiazepines, during the taper<sup>19</sup></li>
<li>Optimize non-opioid management of pain and provide psychosocial support for anxiety related to the taper</li>
<li>Some patients may begin to manifest an Opioid Use Disorder during the taper. Arrange for appropriate treatment and consider naloxone use</li>
</ul>

                                                                                </div>
                                                                    </div>
                                                            </div>
                        </div>
                    </div>
            
                            </div>
        </div>
    </div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px">* <em>Recommendations above have been developed in part from a consensus of expert opinion.</em></p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Options</h5>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="is-style-red-background"> <strong>Putting the evidence in perspective:</strong> While many opioid therapies have 2 or 3 dots under “Evidence level”, denoting a good quality of evidence, this simply means that the studies were well-designed, not that the effect was large. <br><br>Most of the studies were no more than 3 months long, and the overall effect size of opioids is only moderate for pain (corresponding to a 1 or 2 point decrease on a 10-point pain scale) and low for improved function (corresponding to a 10% or smaller improvement in function). <br><br><strong>Non-opioid treatments are considered 1st-line in managing chronic non-cancer pain. Opioids should be used only if non-opioid treatments have failed or cannot be used.</strong><sup>22</sup> </p>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2020/05/stop.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p><strong data-rich-text-format-boundary="true">WATCHFUL DOSE:</strong> Guidelines recommend reassessing the benefit/risk of doses ≥50 MME/day and to “avoid or justify increasing dosage” at doses ≥90 MME/day.<sup>2,18</sup></p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2020/05/stop.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p><strong data-rich-text-format-boundary="true">Oral meperidine</strong>: has no role in the treatment of chronic non-cancer pain because of its poor oral bioavailability and the accumulation of a toxic metabolite.<sup>13</sup></p>
          </div>
        </div>

      </div>
</article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Codeine</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong><sup>1</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Chronic low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><span style="font-size: 14px;"><strong>Level of evidence</strong><sup>1,3</sup><br />
<strong>•••</strong></span></span></p>
<p><span style="font-size: 14px;"><span style="font-size: 14px;"><span style="font-size: 14px;"><strong>Role in therapy</strong><sup>13</sup></span></span></span></p>
<ul>
<li><span style="font-size: 14px;"><span style="font-size: 14px;"><span style="font-size: 14px;">Use only if patient does not respond to non-opioid therapies</span></span></span></li>
<li><span style="font-size: 14px;"><span style="font-size: 14px;"><span style="font-size: 14px;">Among opioids, this is a 1st-line opioid for mild to moderate pain</span></span></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="JN1Fam">View Dosage, Potential Harms &#038; Clinical Pearls</a>
                                      </div>
                                      <div class="modal" data-modal="JN1Fam">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong><sup>13</sup></p>
<ul>
<li><span style="text-decoration: underline;">Immediate release formula:</span> start 15-30mg q4h prn; titration q7d, increase by 15-30mg/d; max 600 mg/d or acetaminophen 4g/d</li>
<li>&gt;<span style="text-decoration: underline;">Controlled release formula:</span> start 50mg q12h; titration q2d, increase by 50mg/d; max 300 mg q12h</li>
</ul>
<p><strong>Potential harms</strong><sup>13</sup></p>
<ul>
<li>Nausea, constipation, drowsiness, dizziness, dry skin/itching, vomiting</li>
<li>Abuse/addiction (risk lower than with stronger opioids)</li>
</ul>
<p><strong>Clinical Pearls</strong></p>
<ul>
<li>When used with acetaminophen, limit max acetaminophen dose to 3.2g/day</li>
<li>Maximum duration of therapy for breastfeeding women = 4 days (some women rapidly metabolize codeine to morphine; causing neonatal toxicity)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Tramadol</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong><sup>1</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Chronic low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><span style="font-size: 14px;"><strong>Level of evidence</strong><sup>1,3</sup><br />
<strong>•••</strong></span></span></p>
<p><span style="font-size: 14px;"><span style="font-size: 14px;"><span style="font-size: 14px;"><strong><span style="font-size: 14px;">Role in therapy</span></strong><sup>13</sup></span></span></span></p>
<ul>
<li><span style="font-size: 14px;"><span style="font-size: 14px;"><span style="font-size: 14px;">Use only if patient does not respond to non-opioid therapies</span></span></span></li>
<li><span style="font-size: 14px;"><span style="font-size: 14px;"><span style="font-size: 14px;">Among opioids, this is a 1st-line opioid for mild to moderate pain</span></span></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="Ms11O4">View Dosage &#038; Potential Harms</a>
                                      </div>
                                      <div class="modal" data-modal="Ms11O4">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong><sup>13</sup></p>
<ul>
<li><span style="text-decoration: underline;">Tramadol/acetaminophen (37.5/325 mg):</span> start 1 tab q4-6h (max 4 tabs/d); titration q7d, increase by 1 tab q4-6h; max 8 tabs/d</li>
<li><span style="text-decoration: underline;">Tramadol immediate release:</span> starting dose (days 1-3) 25 mg qam; titration (as tolerated), day 4-6: 25 mg bid,  Day 7-9: 25 mg tid, Day 10-12: 25 mg qid, Day 13-15: 50 mg tid, Day 16 and thereafter: 50 mg qid</li>
<li><span style="text-decoration: underline;">Tramadol controlled release:</span> start 100-150 mg q24h (depends on brand); titrate q2-7d (depends on brand); max 300-400 mg/d (depends on brand)</li>
</ul>
<p><strong>Potential harms</strong><sup>13</sup></p>
<ul>
<li>Seizure risk (in patients at high risk of seizure or patients on medications that increase serotonin, such as selective serotonin reuptake inhibitors [SSRIs])</li>
<li>Nausea, constipation, drowsiness, dizziness, dry skin/itching, vomiting</li>
<li>Abuse/addiction: (risk may be lower than with other opioids)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Morphine</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong><sup>2</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Chronic low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis (only continue if there is ongoing pain relief; regular review is required)</span></li>
</ul>
<p><span style="font-size: 14px;"><span style="font-size: 14px;"><strong>Level of evidence</strong><sup>1,3</sup><strong><br />
••</strong></span></span></p>
<p><span style="font-size: 14px;"><span style="font-size: 14px;"><strong>Role in therapy</strong><sup>13</sup></span></span></p>
<ul>
<li><span style="font-size: 14px;"><span style="font-size: 14px;">Use only if patient does not respond to non-opioid therapies</span></span></li>
<li><span style="font-size: 14px;"><span style="font-size: 14px;">Among opioids, this is a 2nd-line opioid for mild to moderate pain and a 1st-line opioid for severe pain</span></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="gEOIuU">View Dosage &#038; Potential Harms</a>
                                      </div>
                                      <div class="modal" data-modal="gEOIuU">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong><sup>13</sup></p>
<ul>
<li><span style="text-decoration: underline;">Immediate release:</span> start 5-10 mg q4-6h (max 40 mg/d); titrate: q7d, increase by 5-10 mg/d; max: reassess benefit/risk of doses ≥ 50 MME/ day, avoid or justify increasing dosage at doses ≥ 90 MME/day</li>
<li><span style="text-decoration: underline;">Controlled release:</span> start 10-15 mg q12-24h; titrate q14d, increase by 5-10 mg/d; max: reassess benefit/risk of doses ≥ 50MME/ day, avoid or justify increasing dosage at doses ≥ 90 MME/day</li>
</ul>
<p><strong>Potential harms</strong><sup>13</sup></p>
<ul>
<li>Nausea, constipation, drowsiness, dizziness, dry skin/itching, vomiting</li>
<li>Abuse/addiction: Use with caution in patients with high risk of opioid abuse</li>
<li>Avoid in renal impairment (toxic metabolite can accumulate)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Oxycodone</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong><sup>1</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Chronic low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis (only continue if there is ongoing pain relief; regular review is required)</span></li>
</ul>
<p><span style="font-size: 14px;"><span style="font-size: 14px;"><strong>Level of evidence</strong><sup>1,3</sup><strong><br />
••</strong></span></span></p>
<p><span style="font-size: 14px;"><span style="font-size: 14px;"><span style="font-size: 14px;"><strong>Role in therapy</strong><sup>13</sup></span></span></span></p>
<ul>
<li><span style="font-size: 14px;"><span style="font-size: 14px;"><span style="font-size: 14px;">Use only if patient does not respond to non-opioid therapies</span></span></span></li>
<li><span style="font-size: 14px;"><span style="font-size: 14px;"><span style="font-size: 14px;">Among opioids, this is a 2nd-line opioid for mild to moderate pain and a 1st-line opioid for severe pain</span></span></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="DcPNrm">View Dosage &#038; Potential Harms</a>
                                      </div>
                                      <div class="modal" data-modal="DcPNrm">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong><sup>13</sup></p>
<ul>
<li><span style="text-decoration: underline;">Immediate release:</span> start 5 mg q6h (max 30 mg/d); titrate q7d, increase by 5 mg/d; max: reassess benefit/risk of doses ≥50 MME/ day, avoid or justify increasing dosage at doses ≥ 90 MME/day</li>
<li><span style="text-decoration: underline;">Controlled release:</span> start 10 mg q12h; titrate q14d, increase by 10 mg/d; max: reassess benefit/risk of doses ≥ 50 MME/ day, avoid or justify increasing dosage at doses ≥ 90 MME/day</li>
<li>See <strong>Opioid Manager</strong> for corresponding oxycodone dose</li>
</ul>
<p><strong>Potential harms</strong><sup>13</sup></p>
<ul>
<li>Nausea, constipation, drowsiness, dizziness, dry skin/itching, vomiting</li>
<li>Abuse/addiction: Use with caution in patients with high risk of opioid abuse</li>
</ul>
<p>&nbsp;</p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Hydromorphone</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong><sup>1</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Chronic low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis (only continue if there is ongoing pain relief; regular review is required)</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><sup>1,3</sup><strong><br />
••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong><sup>13</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Use only if patient does not respond to nonopioid therapies</span></li>
<li><span style="font-size: 14px;">Among opioids, this is a 2nd-line opioid for mild to moderate pain and a 1st-line opioid for severe pain</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="jQ30nI">View Dosage &#038; Potential Harms</a>
                                      </div>
                                      <div class="modal" data-modal="jQ30nI">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong><sup>13</sup></p>
<ul>
<li><span style="text-decoration: underline;">Immediate release</span>: start 1-2 mg q4-6h (max 8 mg/d); titrate q7d, increase by 1-2 mg/d; max: reassess benefit/risk of doses ≥ 50 MME/ day, avoid or justify increasing dosage at doses ≥ 90 MME/day</li>
<li><span style="text-decoration: underline;">Controlled release</span>: start 3 mg q12h (max 9 mg/d); titrate q14d, increase by 3 mg/d; max: reassess benefit/risk of doses ≥50 MME/ day, avoid or justify increasing dosage at doses ≥ 90 MME/day</li>
<li>See Opioid Manager for corresponding hydromorphone dose</li>
</ul>
<p><strong>Potential harms</strong><sup>13</sup></p>
<ul>
<li>Nausea, constipation, drowsiness, dizziness, dry skin/itching, vomiting</li>
<li>Abuse/addiction: Use with caution in patients with high risk of opioid abuse</li>
</ul>
<p>&nbsp;</p>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Fentanyl</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong><sup>1</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Chronic low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis (only continue if there is ongoing pain relief; regular review is required)</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><sup>1,3</sup><strong><br />
••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong><sup>13</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Use only if patient does not respond to nonopioid therapies</span></li>
<li><span style="font-size: 14px;">Among opioids, this is a 2nd-line opioid for severe pain</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="oQK3l5">View Dosage &#038; Potential Harms</a>
                                      </div>
                                      <div class="modal" data-modal="oQK3l5">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong><sup>13</sup></p>
<ul>
<li>Only use fentanyl in patients who have taken a morphine equivalent dose (MED) of at least 60- 100 mg/day for at least 2 weeks</li>
<li>Use Opioid Manager to convert from other opioids</li>
<li>Do not switch patients directly from codeine to fentanyl (10% of Caucasian patients lack the enzyme that metabolizes codeine to morphine; these patients may not have developed a tolerance to opioids)</li>
<li>In Ontario, fentanyl patches must be prescribed and dispensed in accordance with the <a href="https://link.cep.health/cncpweb37" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Patch For Patch</a> program</li>
<li>The <a href="https://link.cep.health/cncpweb38" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid Patch Exchange Disposal Tool</a> can help assist with patch exchange</li>
</ul>
<p><strong>Potential harms</strong><sup>13</sup></p>
<ul>
<li>Nausea, constipation, drowsiness, dizziness, dry skin/itching, vomiting</li>
<li>Abuse/addiction: Use with caution in patients with high risk of opioid abuse</li>
<li>Avoid placing sources of heat on top of patch (e.g. heating pads)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Methadone</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong><sup>1</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Chronic low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><sup>1,3</sup><strong><sup><br />
</sup></strong></span><span style="font-size: 14px;"><strong>••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong><sup>13</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Use only if patient does not respond to nonopioid therapies</span></li>
<li><span style="font-size: 14px;">Methadone is primarily used for managing addiction but may sometimes be used to manage pain. Health Canada has removed the exemption on prescribing for methadone. For more information on the new requirements visit <a href="https://link.cep.health/cncpweb41" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">CPSO &#8211; Methadone Program</a></span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="kYhGr6">View Dosage &#038; Potential Harms</a>
                                      </div>
                                      <div class="modal" data-modal="kYhGr6">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong><sup>13</sup></p>
<ul>
<li>Methadone is not intended for initial titration in an opioid trial</li>
<li>Consult a specialist with expertise in methadone treatment</li>
</ul>
<p><strong>Potential harms</strong><sup>13</sup></p>
<ul>
<li>Nausea, constipation, drowsiness, dizziness, dry skin/itching, vomiting</li>
<li>Abuse/addiction: Use with caution in patients with high risk of opioid abuse</li>
<li>Avoid in renal impairment (toxic metabolite can accumulate)</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Tapentadol</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong><sup>1</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Osteoarthritis (studied mainly in knee osteoarthritis)</span></li>
<li><span style="font-size: 14px;">Low back pain</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><sup>1,3</sup><strong><br />
•••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong><sup>13</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Should be considered as an option for pain relief in patients with chronic low back pain and osteoarthritis</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="P03esH">View Dosage &#038; Potential Harms</a>
                                      </div>
                                      <div class="modal" data-modal="P03esH">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong><sup>13</sup></p>
<ul>
<li><span style="text-decoration: underline;">Immediate release</span>: start 50 mg q 4-6 h prn; titrate 50 mg q 4-6 h; max: not recommended daily doses &gt;700 mg on the first day of therapy and 600 mg on subsequent days</li>
<li><span style="text-decoration: underline;">Controlled release</span>: start 50 mg bid (approximately every 12 hours); titration increase by 50 mg bid every 3 days; usual dose: 100-250 mg bid
<ul>
<li>The 50 mg extended-release tablets are intended for short-term use in the initial titration phase only</li>
</ul>
</li>
<li><span style="text-decoration: underline;">Patients currently taking other opioids</span>: Tapentadol has a dual mechanism of action &#8211; muopioid agonist plus norepinephrine reuptake inhibitor. Therefore caution is advised when switching to tapentadol from pure mu-opioids.<sup>55,56</sup></li>
</ul>
<p><strong>Potential harms</strong><sup>13</sup></p>
<ul>
<li>Nausea, constipation, drowsiness, dizziness, dry skin/itching, vomiting, hypotension<sup>55,56</sup></li>
<li>Abuse/addiction<sup>55,56</sup></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Buprenorphine (transdermal)</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong><sup>1</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Chronic low back pain</span></li>
<li><span style="font-size: 14px;">Osteoarthritis</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><sup>1,3</sup><strong><br />
••</strong></span></p>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong><sup>13</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Useful if problems with oral administration</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="P9pJHY">View Dosage &#038; Potential Harms</a>
                                      </div>
                                      <div class="modal" data-modal="P9pJHY">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong><sup>13</sup></p>
<ul>
<li>May be used in opioid-naïve and opioid-experienced patients (in patients taking up to 80 mg oral MME/ day)<sup>57</sup></li>
<li>May cause opioid withdrawal symptoms in patients taking long-term or higher dose opioids before being switched to buprenorphine<sup>58</sup></li>
<li><span style="text-decoration: underline;">Opioid-naïve patients:</span> starting dose: start with the smallest patch 5 mcg/hr, change patch every 7 days; titration: remove current patch and replace with the next highest strength every 7 days as required<br />
Max dose: 20 mcg/hr patch every 7 days</li>
<li>&gt;<span style="text-decoration: underline;">Opioid-experienced patients:</span> Start on 5 mcg/hr or 10 mcg/hr patch, provide adequate rescue medication, and titrate by 5 to 10 mcg/hr every 7 days as required (max 20 mcg/ hr)<sup>60,61</sup></li>
<li>Patches available as 5, 10, 15, and 20 mcg/hr</li>
<li>Tip: If pain occurs at the end of the dosing interval it is usually a sign that the dosage needs to be increased, not that the dosage interval needs to be decreased</li>
</ul>
<p><strong>Potential harms</strong><sup>13</sup></p>
<ul>
<li>Nausea, constipation, drowsiness, dizziness, dry skin/itching, vomiting</li>
<li>Abuse/addiction</li>
<li>Allow 3 weeks before reusing the same patch site<sup>57</sup>, and avoid exposing the patch to direct sunlight (increases absorption)<sup>58</sup></li>
<li>Do not use in people weighing less than 40 kg<sup>57</sup></li>
<li>May accumulate in severe hepatic impairment<sup>58</sup></li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Buprenorphine/naloxone</h6>
                    <p><span style="font-size: 14px;"><strong>Pain type</strong><sup>1</sup></span></p>
<ul>
<li><span style="font-size: 14px;">NA</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Level of evidence</strong><sup>1,3</sup><strong><br />
</strong></span></p>
<ul>
<li><span style="font-size: 14px;">NA</span></li>
</ul>
<p><span style="font-size: 14px;"><strong>Role in therapy</strong><sup>13</sup></span></p>
<ul>
<li><span style="font-size: 14px;">Used for substitution treatment for adults with problematic opioid dependence. The naloxone component is to deter injection and intranasal use and abuse<sup>59<br />
</sup></span></li>
<li><span style="font-size: 14px;">Do not use in opioid-naïve patients</span></li>
</ul>
                                            <a class="button open-modal" href="#" data-modal="JTvYIl">View Dosage &#038; Potential Harms</a>
                                      </div>
                                      <div class="modal" data-modal="JTvYIl">
                      <div class="inner ">
                        <div class="close-wrapper">
                          <a href="" class="close" data-wpel-link="internal">Close</a>
                        </div>
                        <div class="container">
                          <div class="content">
                                                                                      <p><strong>Dosage</strong><sup>13</sup></p>
<ul>
<li>Patients dependent on heroin or short-acting opioids: Start when objective signs of withdrawal occur (<a href="https://link.cep.health/cncpweb40" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Clinical Opioid Withdrawal Scale [COWS]</a> score of 13 or greater), but not less than 6 hours after the patient last used opioids</li>
<li>Patients receiving methadone: first, reduce methadone to minimum dose tolerable by patient, then start buprenorphine/naloxone only when objective signs of withdrawal appear (COWS score of 13 or greater) and generally not less than 24 hours after the patient last used methadone</li>
<li>Starting dose: day 1: 4 mg, then an additional 4 mg dose if needed. Usual dose target for Day 1 is 8-12 mg; t<span style="font-size: 14px;">itration: increase by 2-8 mg to a level that holds the patient in treatment and prevents withdrawal effects; </span><span style="font-size: 14px;">usual maintenance dose: 12 mg to 16 mg once daily, maximum 24 mg daily</span></li>
<li>Once stable, may give twice the patient’s daily dose every other day (e.g. give 16 mg every other day for a patient stabilized on 8 mg daily) or 3 times a week (with twice the daily dose on Monday and Wednesday and three times the daily dose on Friday); do not exceed 24 mg on any one day<sup>59</sup></li>
</ul>
<p><strong>Potential harms</strong><sup>13</sup></p>
<ul>
<li>Should only be prescribed by physician who:
<ul>
<li>Has experience in substitution treatment of opioid dependence</li>
<li>Has completed a recognized education program</li>
</ul>
</li>
<li>Must be dispensed daily under healthcare professional supervision until patient is stable enough to safely store take-home doses</li>
<li>Co-ingestion with alcohol or other CNS depressants could lead to a fatal overdose</li>
<li>Accidental consumption of even one dose by an opioidnaïve person could lead to fatal overdose</li>
<li>Side effects:
<ul>
<li>After first dose: withdrawal effects (e.g. shaking, sweating, headache, pain, muscle aches, nausea)</li>
<li>Other side effects: constipation, anxiety, tiredness, nausea/vomiting, dizziness, orthostatic hypotension<sup>59</sup></li>
</ul>
</li>
</ul>
                                                      </div>
                        </div>
                      </div>
                      <div class="overlay"></div>
                    </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px"><em><strong>LEGEND: CATEGORIES FOR LEVELS OF EVIDENCE </strong>(according to original guidelines’ taxonomy)&nbsp;<br>•••  Highest level of evidence (meta-analyses; systematic reviews of RCTs; RCTs with varying levels of bias)&nbsp;<br>••   Mid-level evidence (systematic reviews of case studies; high quality case control or cohort studies; experimental studies w/o randomization; case reports or studies)&nbsp;<br>•    Low-level evidence (expert opinion and/or clinical experiences of respected authorities/guideline development group)</em></p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Resources</h5>
</div></article>

<article class="block--support-materials ">
  <div class="container two-column">
    <div class="columns is-variable is-8">

      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">For providers</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://link.cep.health/cncpweb1" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">LHIN-specific resources</a></li>
<li><a href="https://link.cep.health/cncpweb39" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Appendix C: for details on evidence, benefits/harms, and dosing</a></li>
<li><a href="https://link.cep.health/cncpweb36" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s1">Opioid Manager</span></a></li>
<li><a href="https://link.cep.health/cncpweb7" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid Tapering Template</a></li>
<li><a href="https://link.cep.health/cncpweb43" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid Use Disorder Tool</a></li>
<li><a href="https://link.cep.health/cncpweb42" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid Treatment Agreement</a></li>
<li><a href="https://link.cep.health/cncpweb16" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">McMaster Health Sciences: Practice toolkit</a></li>
<li><a href="https://link.cep.health/cncpweb18" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Centers for Disease Control Pocket Guide: Tapering opioids for chronic pain</a></li>
<li><a href="https://link.cep.health/cncp16" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid Risk: Urine Drug Testing Guide</a></li>
<li><a href="https://link.cep.health/cncpweb15" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Screening, Brief Intervention, and Referral to Treatment (SBIRT)</a></li>
<li><a href="https://link.cep.health/cncpweb17" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">College of Physicians and Surgeons of Ontario (CPSO): Appropriate Opioid Prescribing</a></li>
<li><a href="https://link.cep.health/cncpweb19" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Ontario Pharmacy Evidence Network (OPEN): Evidence-based deprescribing algorithm for benzodiazepine receptor agonists</a></li>
</ul>
        </div>
      </div>
  
      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">For patients</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://www.tools.cep.health/wp-content/uploads/2020/03/CNCP-PT-resource-for-web-2020.03.30.pdf" data-wpel-link="internal">Printable patient handout with resources on information on pain, non-pharmacological therapies, opioids, support groups and self-management programs</a></li>
<li><a href="https://link.cep.health/cncpweb21" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Centers for Disease Control and Prevention (CDC) – Prescription opioids: What you need to know</a></li>
<li><a href="https://link.cep.health/cncpweb23" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">The Pain Toolkit</a></li>
<li><a href="https://link.cep.health/cncpweb25" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Mike Evans: Best Advice for People Taking Opioid Medication</a></li>
<li><a href="https://link.cep.health/cncpweb27" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Institute for Safe Medication Practices (ISMP) Canada Opioid Stewardship</a></li>
<li><a href="https://link.cep.health/cncpweb29" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">British Columbia Chronic Pain Self-Management Program</a></li>
<li><a href="https://link.cep.health/cncpweb31" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Fact Sheet: Chronic Pain</a></li>
<li><a href="https://link.cep.health/cncpweb22" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">McMaster University: Messages for patients taking opioids</a></li>
<li><a href="https://link.cep.health/cncpweb24" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">RNAO Fact sheets: Helping people manage their pain</a></li>
<li><a href="https://link.cep.health/cncpweb26" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Understanding Pain in less than 5 minutes, and what to do about it!</a></li>
<li><a href="https://link.cep.health/cncpweb28" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">People in Pain Network</a></li>
</ul>
        </div>
      </div>

    </div>
  </div>
</article>						</div>
					</div>
				</section>
							<section class="main-section" id="intervention-management-and-referral" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Intervention management and referral								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Ensure that all necessary and relevant information, as required by the clinic or specialist, is included when initiating a referral.</p>
          </div>
        </div>

      </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Options</h5>
</div></article>

<article class="block--table ">
<div class="container">
  <div class="table no-header inner-border-blue ">

        
                    <div class="rows">

                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:30%;">
                                            <h6><strong>Psychological therapy</strong></h6>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:70%;">
                                            <p><strong>Consider when</span></strong><span style="font-size: 14px;"><sup>1</sup></span></p>
<ul>
<li>Patient has moderate to high levels of distress</span></li>
<li>Patient has difficulty adjusting to a life with pain</span></li>
<li>Patient is struggling to change their behaviour and maintain normal activities</span></li>
<li>Patient is referred to specialist pain service</span></li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:30%;">
                                            <h6><strong>Pain specialist service  (may include interventional management)</strong></h6>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:70%;">
                                            <p><strong>Consider when</span></strong><span style="font-size: 14px;"><sup>1</sup></span></p>
<ul>
<li>Treatment failure after trial of 4 drugs for neuropathic pain</span></li>
<li>Opioid dose is greater than 90 MME<sup>2</sup></span></li>
<li>Inadequate response to non-specialist management</span></li>
</ul>
<p><strong>Features</span></strong></p>
<ul>
<li>Interventional procedures can provide short-term relief of pain, though some interventions are associated with rare but significant adverse outcomes (e.g. stroke, death)</span></li>
<li>Consider the following procedures for the specified conditions:</span>
<ul>
<li>Lumbar or cervical epidurals in hospital-based centres (e.g. spinal stenosis, discogenic pain +/- radicular pain)</span></li>
<li>Facet joint injections, median branch blocks (e.g. facet joint pain)</span></li>
<li>Radiofrequency nerve ablation (e.g. facet and sacroiliac joint pain)</span></li>
<li>Spinal cord stimulators (e.g. low back and associated limb-based pain in failed back surgery)</span></li>
<li>Trigger point injections (e.g. myofascial pain syndromes)</span></li>
</ul>
</li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                                    <div class="row">

                                                    <div class="cols">
                        
                                
                                                                            <div class="col 1" style="flex-basis:30%;">
                                            <h6><strong>Multidisciplinary pain management program</strong></h6>
                                        </div>
                                    
                                
                                                                            <div class="col 2" style="flex-basis:70%;">
                                            <p><strong>Consider when</span></strong><span style="font-size: 14px;"><sup>1</sup></span></p>
<ul>
<li>Patient has poor functional capacity</span></li>
<li>Patient has moderate to high levels of distress</span></li>
<li>Patient has failed to benefit from other, less comprehensive therapies</span></li>
<li>If referring patient for CRPS, urgent consultation and management required</span></li>
</ul>
<p><strong>Features</span></strong></p>
<ul>
<li>Rehabilitation and exercise therapy</span></li>
<li>Patient education</span></li>
<li>Vocational therapy</span></li>
<li>Medical management</span></li>
</ul>
                                        </div>
                                    
                                                            </div>
                        
                    </div>
                
            </div>
        
        
    </div>
</div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Resources</h5>
</div></article>

<article class="block--support-materials ">

  <div class="container wide">
    <div class="inner">
              <div class="columns">
                      <div class="column icon">
              <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
            </div>
                                <div class="column">
              <strong class="heading">For providers</strong>
            </div>
                  </div>
                    <div class="columns">
                      <div class="column">
              <div class="columns is-flex is-gapless">
<div class="column is-10-mobile is-11">
<ul>
<li><a href="https://link.cep.health/cncpweb1" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">LHIN-specific resources</a></li>
<li style="text-align: left;"><a href="https://link.cep.health/cncpweb8" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Medical Mentoring for Addictions and Pain (MMAP)</a></li>
<li><a href="https://link.cep.health/cncpweb9" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Project ECHO</a></li>
<li><a href="https://link.cep.health/cncpweb10" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">eConsult (OTN Hub)</a></li>
<li><a href="https://link.cep.health/cncpweb11" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Toronto Academic Pain Medicine Institute (TAPMI)</a></li>
<li><a href="https://link.cep.health/cncpweb12" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">The Inter-professional Spine Assessment and Education Clinics (ISAEC)</a></li>
</ul>
</div>
</div>
            </div>
                            </div>
          </div>
  </div>

</article>						</div>
					</div>
				</section>
							<section class="main-section" id="supporting-materials-and-resources" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Supporting materials and resources								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">For providers </h5>
</div></article>

<article class="block--support-materials ">
  <div class="container two-column">
    <div class="columns is-variable is-8">

      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">Clinical resources</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://link.cep.health/cncpweb39" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Management of Chronic Non-Cancer Pain Appendices A-C</a></li>
<li><a href="https://link.cep.health/cncpweb2" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Complex Regional Pain Syndrome (CRPS)</a></li>
<li><a href="https://link.cep.health/cncpweb3" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s2">Brief Pain Inventory (BPI)</span></a></li>
<li><a href="https://link.cep.health/cncpweb4" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s2">PHQ-9</span></a></li>
<li><a href="https://link.cep.health/cncpweb5" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s2">GAD-7 </span></a></li>
<li><a href="https://link.cep.health/cncpweb13" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s1">CORE Neck and Headache tool</span></a></li>
<li><a href="https://link.cep.health/cncpweb14" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s1">CORE Back Pain tool </span></a><b></b></li>
<li><a href="https://link.cep.health/cncpweb6" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s2">Opioid Risk Tool</span></a></li>
<li><a href="https://link.cep.health/cncpweb36" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid Manager</a></li>
<li><a href="https://link.cep.health/cncpweb7" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s1">Opioid Tapering Template</span></a><b></b></li>
<li><a href="https://link.cep.health/cncpweb43" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid Use Disorder Tool</a></li>
<li><a href="https://link.cep.health/cncpweb20" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid Risk: Urine Drug Testing Guide</a></li>
<li><a href="https://link.cep.health/cncpweb42" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Opioid treatment agreement</a></li>
<li><a href="https://link.cep.health/cncpweb15" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">SBIRT (Screening, Brief Intervention, and Referral to Treatment) </a></li>
<li><a href="https://link.cep.health/cncpweb18" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Centers for Disease Control Pocket Guide: Tapering opioids for chronic pain</a><b></b></li>
<li><a href="https://link.cep.health/cncpweb19" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Ontario Pharmacy Evidence Network (OPEN): Evidence-based deprescribing algorithm for benzodiazepine receptor agonists</a><b></b></li>
</ul>
        </div>
      </div>
  
      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">Clinical supports</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://link.cep.health/cncpweb1" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">LHIN-specific resources</a></li>
<li><a href="https://link.cep.health/cncpweb8" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Medical Mentoring for Addictions and Pain (MMAP)</a></li>
<li><a href="https://link.cep.health/cncpweb9" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s2">Project ECHO</span></a></li>
<li><a href="https://link.cep.health/cncpweb10" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s2">eConsult (OTN Hub)</span></a><b></b></li>
<li><a href="https://link.cep.health/cncpweb11" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Toronto Academic Pain Medicine Institute (TAPMI)</a><b></b></li>
<li><a href="https://link.cep.health/cncpweb12" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">The Inter-professional Spine Assessment and Education Clinics (ISAEC)</a></li>
<li><a href="https://link.cep.health/cncpweb16" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">McMaster Health Sciences: Practice toolkit</a></li>
<li><a href="https://link.cep.health/cncpweb17" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">College of Physicians and Surgeons of Ontario (CPSO): Appropriate Opioid Prescribing </a></li>
</ul>
        </div>
      </div>

    </div>
  </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading"><strong>For patients</strong></h5>
</div></article>

<article class="block--support-materials ">
  <div class="container two-column">
    <div class="columns is-variable is-8">

      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">Information on pain</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://link.cep.health/cncpweb23" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">The Pain Toolkit</a></li>
<li><a href="https://link.cep.health/cncpweb24" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">RNAO Fact sheets: Helping people manage their pain</a></li>
<li><a href="https://link.cep.health/cncpweb26" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Understanding Pain in less than 5 minutes, and what to do about it!</a></li>
<li><a href="https://link.cep.health/cncpweb31" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s1">Fact Sheet: Chronic Pain</span></a></li>
</ul>
        </div>
      </div>
  
      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">Information on non-pharmacological therapies</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://link.cep.health/cncpweb30" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">NeuroNovo Centre for Mindful Solutions (formerly “for Mindfulness- Based Chronic Pain Management”)</a></li>
<li><a href="https://link.cep.health/cncpweb32" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Webinar: Intro to Mindfulness for Chronic Pain (5 part series)</a></li>
<li><a href="https://link.cep.health/cncpweb33" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Webinar: Yoga for people in pain (5 part series)</a></li>
<li><a href="https://link.cep.health/cncpweb35" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Centre for Mindfullness Studies</a></li>
</ul>
        </div>
      </div>

    </div>
  </div>
</article>

<article class="block--support-materials ">
  <div class="container two-column">
    <div class="columns is-variable is-8">

      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">Information on opioids</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://link.cep.health/cncpweb21" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Centers for Disease Control and Prevention (CDC) &#8211; Prescription opioids: What you need to know</a></li>
<li><a href="https://link.cep.health/cncpweb22" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">McMaster University: Messages for patients taking opioids</a></li>
<li><a href="https://link.cep.health/cncpweb25" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Mike Evans: Best Advice for People Taking Opioid Medication</a></li>
<li><a href="https://link.cep.health/cncpweb27" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Institute for Safe Medication Practices (ISMP) Canada Opioid Stewardship</a></li>
</ul>
        </div>
      </div>
  
      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading">Support groups and self-management programs</strong>
                </div>
                          </div>
                    <ul>
<li><a href="https://link.cep.health/cncpweb28" target="_blank" rel="noopener external noreferrer" data-wpel-link="external"><span class="s1">People in Pain Network</span></a></li>
<li><a href="https://link.cep.health/cncpweb29" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">British Columbia Chronic Pain Self-Management Program</a></li>
<li><a href="https://link.cep.health/cncpweb34" target="_blank" rel="noopener external noreferrer" data-wpel-link="external">Canadian Mental Health Association (CMHA)</a></li>
</ul>
        </div>
      </div>

    </div>
  </div>
</article>

<article class="block--file-download ">
<div class="container">
  <a href="https://tools.cep.health/wp-content/uploads/2020/03/CNCP-PT-resource-for-web-2020.03.30.pdf" download="" target="_blank" class="inner" data-wpel-link="internal">
    <div class="inner-wrapper">
      <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/file.svg" />
      <div class="filename-wrapper">
        <h6>Download a printable patient handout with all resources and supports</h6>
        <span class="filename">CNCP-PT-resource-for-web-2020.03.30.pdf</span>
      </div>
    </div>
    <span class="button" target="_blank"><i class="icon-arrow-down-circ"></i> Download</span>
  </a>
</div>
</article>

<article class="block--table-with-icon "><div class="container">
      <div class="table no-header">
        <div class="body">
          </div>
  </div>

</div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px">*These supporting materials and resources are hosted by external organizations and as such, the accuracy and accessibility of their links are not guaranteed. CEP will make every effort to keep these links up to date.</p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="references" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								References								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--references ">
<div class="container">

                        <ul>
               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [1]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Scottish Intercollegiate Guideline Network (SIGN). Sign Guideline 136: Management of chronic pain. 2013.</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [2]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Centers for Disease Control and Prevention (CDC): CDC Guideline for Prescribing Opioids for Chronic Pain. 2016; 65(1).</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [3]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Canada: Michael G. DeGroote National Pain Centre. 2017 [cited 2018 July 2].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [4]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Registered Nurses’ Association of Ontario. Assessment and Management of Pain (3rd ed.). Toronto, ON: Registered Nurses’ Association of Ontario. 2013.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [5]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Centre for Effective Practice and University Health Network (November 2017). Opioid Manager. Toronto. [cited 2018 July 2].</span></p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [6]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Nicholas MK, Linton SJ, Watson PJ, Main CJ and ‘Decade of the Flags’ Working Group. Early identification and management of psychological risk factors (“yellow flags”) in patients with low back pain: a reappraisal. Phys Ther 2011; 91(5):737-53.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [7]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Bruckenthal P. Motivational interviewing in managing pain. [cited 2016 August 12].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [8]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Pain Toolkit. Motivational interviewing: a way of talking. [cited 2016 August 12].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [9]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Arthritis Canada. Physical activity &amp; arthritis. [cited 2016 August 12].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [10]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Centers for Disease Control and Prevention (CDC): Physical activity for arthritis. [cited 2016 July 12].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [11]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Office of Disease Prevention and Health Promotion (ODPHP). Physical activity guidelines advisory committee report. [cited 2016 August 12].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [12]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">American College of Rheumatology (ACR). ACR OA Guidelines: Non-pharmacological – knee and hip. 2009. [cited 2016 September 8].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [13]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Kahan M, Mailis-Gagnon A, Wilson L, Srivastava A. Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain: Clinical summary for family physicians. Part 1: General population. Can Fam Physician 2011; 57:1257-66.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [14]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-88.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [15]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-88.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [16]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">College of Family Physicians of Canada (CFPC). Authorizing Dried Cannabis for Chronic Pain or Anxiety: Preliminary Guidance from the College of Family Physicians of Canada. Mississauga, ON: College of Family Physicians of Canada; 2014. [cited 2016 September 8].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [17]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Department of Family and Community Medicine. University of Toronto. Chronic pain management one-pager. 2013. [cited 2016 August 8].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [18]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Centre for Addiction and Mental Health. Prescription Opioid Policy Framework. Toronto: CAMH. 2016. [cited 2016 October 30].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [19]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Pottie K, Thompson W, Davies S, Grenier J, Sadowski C, Welch V, Holbrook A, Boyd C, Swenson JR, Ma A, Farrell B. 2016. Evidence-based clinical practice guideline for deprescribing benzodiazepine receptor agonists. (Unpublished manuscript) [cited 2016 August 1].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [20]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Busch AJ, Barber KA.R. Overend TJ, Peloso PMJ, Schachter CL. Exercise for treating fibromyalgia syndrome. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD003786. DOI: 10.1002/14651858.CD003786.pub2.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [21]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Bussing A, Osterman T, Ludtke R, Michalsen A. Effects of yoga interventions on pain and pain-associated disability: A meta-analysis. The Journal of Pain 2012;13(1):1-9.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [22]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Du S, Yuan C, Xiao X, Chu J, Qiu Y, Qian H. Self-management programs for chronic musculoskeletal pain conditions: a systematic review and meta-analysis. Patient Educ Couns. 2011;85(3):e299-301.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [23]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Williams ACDC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database of Systematic Reviews. 2012;11.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [24]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">RxFiles. Chronic non-malignant pain (CNMP). 2005. General pharmacological considerations: Supplement tables.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [25]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Tylenol Extra Strength [product labelling]. McNeil Consumer Healthcare; February 5, 2015.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [26]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Osteoarthritis Research Society International (OARSI). OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and cartilage 2014;22:363-388.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [27]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Voltaren/Voltaren SR [product monograph]. Dorval, QC: Novartis Pharmaceuticals Canada Inc.; June 21, 2016.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [28]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Aleve [product monograph]. Mississsauga ON; Bayer Inc. Consumer Care; January 8, 2015.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [29]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">RxFiles. Pain management in older adults. 2014.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [30]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Celebrex [product monograph]. Kirkland, QC: Pfizer Canada Inc. 2016.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [31]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Arthrotec [product monograph]. Kirkland QC: Pfizer Canada Inc. 2015.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [32]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Advil Arthritis Pain [product monograph]. Mississauga, ON: Pfizer Consumer Healthcare Inc. 2013.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [33]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Advil Tablets, Caplets, Gel Caplets, Extra Strength Caplets, Muscle and Joint, and 12 hour [product monograph]. Mississauga, ON: Pfizer Consumer Healthcare Inc. 2015.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [34]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Mobicox [product monograph]. Burlington ON: Boehringer Ingelheim Canada Ltd. 2014.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [35]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Apo-Naproxen [product monograph]. Toronto, ON: Apotex Inc.; 2015.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [36]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Tegretol [product monograph]. Dorval, QC: Novartis Pharmaceuticals Canada Inc. 2014.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [37]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Garnett WR, St. Louis EK, Henry TR, Bramley T. Transitional polytherapy: Tricks of the trade for monotherapy to monotherapy AED conversions. Current Neuropharmacology. 2009;7:83-95.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [38]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Neurontin [product monograph]. Kirkland, QC: Warner-Lambert Company LLC. 2016.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [39]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Zhang L, Rainka M, Freeman R, et al. A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). J Pain. 2013;14(6):590-603.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [40]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Lyrica [product monograph]. Kirkland, QC: Pfizer Canada Inc. 2014.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [41]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">National Health Service (NHS). Deprescribing: a practical guide. 2015.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [42]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Ramaswamy S, Malik S, Dewan V. Tips to manage and prevent discontinuation symptoms. Current Psychiatry. 2005;4(9):29-44.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [43]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Hogan DB. Strategies for discontinuing antipsychotic medications. CSG Journal of CME 2014;4(2):14-18.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [44]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Shelton RC. Steps following attainment of remission: Discontinuation of antidepressant therapy.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [45]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Cymbalta [product monograph: Canada]. Toronto ON: Eli Lilly Canada Inc. 2016.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [46]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Cymbalta [product monograph: Australia]. Australia: Eli Lilly. 2015.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [47]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Apo-Fluoxetine [product monograph]. Toronto, ON: Apotex Inc. 2013.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [48]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Pennsaid [product monograph]. Montreal, QC: Paladin Labs Inc. 2010.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [49]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Voltaren Emulgel [product monograph]. Mississauga, ON: GlaxoSmithKline Consumer Healthcare Inc. 2016.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [50]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">National Institute for Health and Care Excellence (NICE). Osteoarthritis: Care and management. 2014 [cited 2016 September 8].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [51]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Myoflex.ca. Extra Strength.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [52]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Sativex [product monograph]. Toronto, ON: Bayer Inc. 2012.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [53]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Cesamet [product monograph]. Montreal, QC: Valeant Canada Limited. 2009.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [54]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Ontario Ministry of Health and Long-Term Care. Ontario Naloxone Pharmacy Program.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [55]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Nucynta [product monograph]. Toronto, ON: Janssen Inc. August 4, 2014.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [56]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Nucynta Extended-Release [product monograph]. Toronto, ON: Janssen Inc. August 4, 2014.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [57]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">BuTrans [product monograph]. Pickering, ON: Purdue Pharma; August 5, 2016.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [58]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">RxFiles. Q&amp;A Summary: BuTrans patch. September 2010.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [59]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Suboxone [product monograph]. Scarborough, ON: RBI Specialized Importation Co. Inc. August 24, 2015.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [60]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">College of Physicians and Surgeons of Ontario (CPSO). Prescribing drugs.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [61]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Ontario College of Pharmacists (OCP). Prescription regulation summary chart.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [62]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Ontario Ministry of Health and Long-Term Care. Ontario’s Narcotics Strategy.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [63]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Ontario Ministry of Health and Long-Term Care. Important notice regarding changes to the Ontario Drug Benefit (ODB) program funding of opioid medications.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [64]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">MedSask (University of Saskatchewan). Switching opioids using equivalence tables.</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [65]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Ultram [product monograph].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [66]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Anaprox [product monograph].</p>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [67]
                    </div>

                    <div class="column">
                      <p><span style="font-size: 12px;">Centre for Effective Practice. (February 2018). Opioid Tapering Template: Ontario. Toronto: Centre for Effective Practice. [cited 2018 July 2].</p>
                    </div>
                  </li>

                            </ul>
           
</div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p></p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="legal" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Legal								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--legal-text ">
<div class="container">
  <div class="columns is-gapless">
    <div class="column is-8 text">
      <div class="inner">
        <p>This Tool was developed as part of the Knowledge Translation in Primary Care Initiative, led by Centre for Effective Practice with collaboration from the Ontario College of Family Physicians and the Nurse Practitioners’ Association of Ontario. Clinical leadership for the development of the tool was provided by Dr. Arun Radhakrishnan, MSc, MD, CM CCFP and was subject to external review by health care providers and other relevant stakeholders. This Tool was funded by the Government of Ontario as part of the Knowledge Translation in Primary Care Initiative.</p>
<p>This tool was developed for licensed health care professionals in Ontario as a guide only and does not constitute medical or other professional advice. Health care professionals are required to exercisetheir own clinical judgment in using this Tool. Neither the Centre for Effective Practice (“CEP”), Ontario College of Family Physicians, Nurse Practitioners’ Association of Ontario, Government of Ontario, nor any of their respective agents, appointees, directors, officers, employees, contractors, members or volunteers: (i) are providing medical, diagnostic or treatment services through this Tool; (ii) to the extent permitted by applicable law, accept any responsibility for the use or misuse of this Tool by any individual including, but not limited to, primary care providers or entity, including for any loss, damage or injury (including death) arising from or in connection with the use of this Tool, in whole or in part; or (iii) give or make any representation, warranty or endorsement of any external sources referenced in this Tool (whether specifically named or not) that are owned or operated by third parties, including any information or advice contained therein.</p>
<p><em>Management of Chronic Non-Cancer Pain is a product of the Centre for Effective Practice. Permission to use, copy, and distribute this material for all non-commercial and research purposes is granted, provided the above disclaimer, this paragraph and the following paragraphs, and appropriate citations appear in all copies, modifications, and distributions. Use of the Management of Chronic Non-Cancer Pain for commercial purposes or any modifications of the Tool are subject to charge and use must be negotiated with the Centre for Effective Practice  (Email: info@cep.health).</em></p>
<p><img decoding="async" class="size-medium wp-image-327 alignnone" src="http://tools.cep.health/wp-content/uploads/2019/10/CCLicense.svg" alt="" /></p>
      </div>
    </div>
    <div class="column is-4 logos">
      <div class="inner">
                  <div>
            
                <p>
                  Developed by:                </p>

                
                  <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/CEP-Logo-Color.svg" />

                
            
                <p>
                  In collaboration with:                </p>

                
                  <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2020/02/OCFP_Logo_rgb_tagline.png" />

                
                  <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/NPAO-Logo.svg" />

                
                      </div>
              </div>
    </div>
  </div>
</div>
</article>						</div>
					</div>
				</section>
			
		</section>
  </main>

<div class="utility-bar">
    <button data-search-tool-open class="utility-button search-button"><i class="icon icon-search"></i></button>
    <a href="#top-of-sections" class="utility-button back-to-top"><i class="icon icon-arrow-up"></i></a>
</div>
<div class="global-modal"></div>

<script type="speculationrules">
{"prefetch":[{"source":"document","where":{"and":[{"href_matches":"\/*"},{"not":{"href_matches":["\/wp-*.php","\/wp-admin\/*","\/wp-content\/uploads\/*","\/wp-content\/*","\/wp-content\/plugins\/*","\/wp-content\/themes\/cep-tools\/*","\/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]}
</script>
<!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Obesity management HTML - enhance confidence -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'hhgajtyemrlknjsvrsd5');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: RSV HTML - change in patient care -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'tkia37pcyyahx6opqim2');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Secure Messaging -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'ngtztpck7tvpbcvakl7d');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 AI LC - fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'f2bzjhvjmeyfqkxxjggz');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Social Rxing -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'qgchslypk4toxdtgsfsf');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML COPD -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'cfontzigzdapzyxtbhg4');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Type 2 DM Insulin -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'nflzw9az1mcray2ltc4m');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Type 2 DM Non-Insulin -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'edlo1w0s0lujgciyjgf9');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML ME/CFS -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'ybbyul2ujyofvsznkiti');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML FM -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'doewskxay35gb860nodl');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Role Q -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'wm0xaeyycxvhthxjz76n');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML POTS -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'iqff27bs0pszfabitkgw');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML HF -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'xfup8pda84l5bd0udyje');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML A&D -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'xokl1h6esysgo5wdkq9d');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2022.11 E2P Patient Resource Page -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'jaxkt0icjnuu0z43iuik');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.11 MAID - Measuring knowledge -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'vso3vlstnsfjgeuogzry');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.11 Fall Prevention & MGMT Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'awihu5noxqqj5s7iasv8');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 PPIs - Change prescribing -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'cdikvvptidch9oj1o56k');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 Chronic Insomnia HTML - Increase Confidence -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'qeu7gqedkzjnotzskhln');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 Non-Medical Cannabis Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'okkbvdzprjjylm7wjkhe');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.07 ADHD Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'rxekv8i4pwnmp4zvclcm');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2020.05 COVID-19 - Change the way you will provide care for your patients? -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'koz3ranojk5yi8c5wmpe');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2020.07 CNCP - change in patient care -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'e6m4njfonyv93sqcttlx');</script>
<!-- / OptinMonster -->		<!-- Google Tag Manager (noscript) snippet added by Site Kit -->
		<noscript>
			<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WLFDZV" height="0" width="0" style="display:none;visibility:hidden"></iframe>
		</noscript>
		<!-- End Google Tag Manager (noscript) snippet added by Site Kit -->
				<script type="text/javascript">
		var hhgajtyemrlknjsvrsd5_shortcode = true;var tkia37pcyyahx6opqim2_shortcode = true;var ngtztpck7tvpbcvakl7d_shortcode = true;var f2bzjhvjmeyfqkxxjggz_shortcode = true;var qgchslypk4toxdtgsfsf_shortcode = true;var cfontzigzdapzyxtbhg4_shortcode = true;var nflzw9az1mcray2ltc4m_shortcode = true;var edlo1w0s0lujgciyjgf9_shortcode = true;var ybbyul2ujyofvsznkiti_shortcode = true;var doewskxay35gb860nodl_shortcode = true;var wm0xaeyycxvhthxjz76n_shortcode = true;var iqff27bs0pszfabitkgw_shortcode = true;var xfup8pda84l5bd0udyje_shortcode = true;var xokl1h6esysgo5wdkq9d_shortcode = true;var jaxkt0icjnuu0z43iuik_shortcode = true;var vso3vlstnsfjgeuogzry_shortcode = true;var awihu5noxqqj5s7iasv8_shortcode = true;var cdikvvptidch9oj1o56k_shortcode = true;var qeu7gqedkzjnotzskhln_shortcode = true;var okkbvdzprjjylm7wjkhe_shortcode = true;var rxekv8i4pwnmp4zvclcm_shortcode = true;var koz3ranojk5yi8c5wmpe_shortcode = true;var e6m4njfonyv93sqcttlx_shortcode = true;		</script>
		<style id='core-block-supports-inline-css' type='text/css'>
.wp-container-core-columns-is-layout-9d6595d7{flex-wrap:nowrap;}
</style>
<script>(function(d){var s=d.createElement("script");s.type="text/javascript";s.src="https://a.omappapi.com/app/js/api.min.js";s.async=true;s.id="omapi-script";d.getElementsByTagName("head")[0].appendChild(s);})(document);</script><script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/vendor.min.js" id="vendor-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/app.min.js?ver=1674670088" id="app-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/glossary-by-codeat/assets/js/off-screen.js?ver=2.3.5" id="glossary-off-screen-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/assets/js/app/modules/slider.js?ver=6.4.2" id="block-acf-drug-options-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/optinmonster/assets/dist/js/helper.min.js?ver=2.16.20" id="optinmonster-wp-helper-js"></script>
		<script type="text/javascript">var omapi_localized = {
			ajax: 'https://tools.cep.health/wp-admin/admin-ajax.php?optin-monster-ajax-route=1',
			nonce: '54d7109d0e',
			slugs:
			{"hhgajtyemrlknjsvrsd5":{"slug":"hhgajtyemrlknjsvrsd5","mailpoet":false},"tkia37pcyyahx6opqim2":{"slug":"tkia37pcyyahx6opqim2","mailpoet":false},"ngtztpck7tvpbcvakl7d":{"slug":"ngtztpck7tvpbcvakl7d","mailpoet":false},"f2bzjhvjmeyfqkxxjggz":{"slug":"f2bzjhvjmeyfqkxxjggz","mailpoet":false},"qgchslypk4toxdtgsfsf":{"slug":"qgchslypk4toxdtgsfsf","mailpoet":false},"cfontzigzdapzyxtbhg4":{"slug":"cfontzigzdapzyxtbhg4","mailpoet":false},"nflzw9az1mcray2ltc4m":{"slug":"nflzw9az1mcray2ltc4m","mailpoet":false},"edlo1w0s0lujgciyjgf9":{"slug":"edlo1w0s0lujgciyjgf9","mailpoet":false},"ybbyul2ujyofvsznkiti":{"slug":"ybbyul2ujyofvsznkiti","mailpoet":false},"doewskxay35gb860nodl":{"slug":"doewskxay35gb860nodl","mailpoet":false},"wm0xaeyycxvhthxjz76n":{"slug":"wm0xaeyycxvhthxjz76n","mailpoet":false},"iqff27bs0pszfabitkgw":{"slug":"iqff27bs0pszfabitkgw","mailpoet":false},"xfup8pda84l5bd0udyje":{"slug":"xfup8pda84l5bd0udyje","mailpoet":false},"xokl1h6esysgo5wdkq9d":{"slug":"xokl1h6esysgo5wdkq9d","mailpoet":false},"jaxkt0icjnuu0z43iuik":{"slug":"jaxkt0icjnuu0z43iuik","mailpoet":false},"vso3vlstnsfjgeuogzry":{"slug":"vso3vlstnsfjgeuogzry","mailpoet":false},"awihu5noxqqj5s7iasv8":{"slug":"awihu5noxqqj5s7iasv8","mailpoet":false},"cdikvvptidch9oj1o56k":{"slug":"cdikvvptidch9oj1o56k","mailpoet":false},"qeu7gqedkzjnotzskhln":{"slug":"qeu7gqedkzjnotzskhln","mailpoet":false},"okkbvdzprjjylm7wjkhe":{"slug":"okkbvdzprjjylm7wjkhe","mailpoet":false},"rxekv8i4pwnmp4zvclcm":{"slug":"rxekv8i4pwnmp4zvclcm","mailpoet":false},"koz3ranojk5yi8c5wmpe":{"slug":"koz3ranojk5yi8c5wmpe","mailpoet":false},"e6m4njfonyv93sqcttlx":{"slug":"e6m4njfonyv93sqcttlx","mailpoet":false}}		};</script>
				<script type="text/javascript">var omapi_data = {"object_id":68657,"object_key":"tools","object_type":"post","term_ids":[],"wp_json":"https:\/\/tools.cep.health\/wp-json","wc_active":false,"edd_active":false,"nonce":"9051981ff5"};</script>
		
  </body>
</html>
